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The Role of Pericyte Loss in Adult Retinal Microvascular Stability:  
Implications for Diabetic Retinopathy 
 
ABSTRACT 
Diabetes affects more than 382 million people worldwide and can lead to vision loss as a 
result of progressive degeneration of the neurovascular unit in the retina, a condition 
known as diabetic retinopathy (DR). Early stage DR is characterized by 
microangiopathies including microaneurysms, microhemorrhages, and hyper-
permeability. Analyses of postmortem human retinal tissue and retinas from animal 
models indicate that degeneration of the pericytes, the cells that make up the outer layer 
of capillaries, is an early event in DR; however, the relative contribution of specific 
cellular components to DR pathobiology has been difficult to dissect due to the 
complexity of existing models.  
To directly assess the consequences of pericyte death on retinal microvascular integrity, I 
used a mouse model (iDTR; M-Cre) conditionally expressing a simian diphtheria toxin 
receptor (DTR) controlled by the smooth muscle myosin heavy chain Cre (M-Cre) 
promoter. Upon induction of Cre, the simian DTR is expressed in pericytes and smooth 
muscle cells, which therefore become diphtheria toxin (DT) sensitive. Administration of 
DT to these mice causes mural cell loss. Five days after the first DT injection, iDTR; M-
Cre mice developed microaneurysms, acellular capillaries, and increased vascular 
permeability, vascular changes that are characteristic of background DR. 
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To measure pericyte loss and acellular capillaries and to avoid bias and ambiguities 
associated with manual analysis, automated techniques were established to reliably 
quantify pericytes and endothelial cells, as well as acellular capillaries in the mouse 
retina. Using these algorithms, DT-treated iDTR; M-Cre mice were shown to have a 7-
15% decrease in pericytes compared to controls. Furthermore, there were twice as many 
acellular capillaries detected in the iDTR; M-Cre mice as compared to controls.  
Using a mouse model of inducible mural cells loss, I have demonstrated a direct role for 
pericyte loss in the development of microangiopathies observed in DR without the 
confounding metabolic factors present in existing DR models. These results suggests that 
preventing or delaying pericyte dropout will avert or attenuate the retinal pathology 
associated with diabetes and highlight a potential for future novel therapies. 
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PREFACE 
In this chapter, Figure 1 has been adapted with permission from the 6th edition textbook, 
“Human Anatomy & Physiology,” by Elaine N. Marieb published in 2003 (page 718), the 
copyright of which is held by Pearson Education, Inc. Figures 2 and 3 have been adapted 
with permission from the article, “Fenestrated Subendothelial Basement Membranes in 
Human Retinal Capillaries,” by Edward C. Carlson in Investigative Ophthalmology & 
Visual Science, January 1989, Vol. 30, pages 1923-1932, the copyright of which is held 
by The Association for Research in Vision and Ophthalmology, Inc. Figure 4 has been 
adapted with permission from the article, “Pericytes: Developmental, Physiological, and 
Pathological Perspectives, Problems, and Promises,” by Annika Armulik, Guillem 
Genové, and Christer Betsholtz in Developmental Cell, August 2011, Vol. 21, pages 193-
215, the copyright of which is held by Elsevier. Table 1 has been adapted with 
permission from the article, “Update on animal models of diabetic retinopathy: from 
molecular approaches to mice and higher mammals,” by Remya Robinson, Veluchamy 
Barathi, Shyam Chaurasia, Tien Wong, and Tim Kern in Disease Models & Mechanisms, 
July 2012, Vol. 5, pages 444-456, the copyright of which is held by The Company of 
Biologists, Ltd.  
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INTRODUCTION 
Overview of the Vasculature  
The cardiovascular system consists of two components: systemic circulation and 
pulmonary circulation. For the purposes of this introduction, I will focus on systemic 
circulation, the process by which oxygenated blood travels from the heart to the tissues 
and is returned to the heart deoxygenated. In the cardiac cycle, oxygenated blood flows 
from the left atrium via the aorta to the arteries into the arterioles and finally into the 
capillaries, where nutrients are transported to the peripheral tissues (Guyton 1987; Ross 
1989; Marieb 2004). From the capillaries in peripheral tissues, deoxygenated blood then 
flows from the venules to the veins through the vena cava and finally to the right atrium. 
Three major vessel types make up the vascular tree: arteries, veins, and capillaries. The 
arteries transport oxygenated blood away from the heart to the tissues under high 
pressure. Conversely, the veins carry deoxygenated blood from the tissues toward the 
heart under low pressure. Capillaries connect the arterioles and venules, which are part of 
the microvasculature that sprout from the arteries and veins, respectively. Furthermore, 
the capillaries are the site of transport of fluid, nutrients, gases, and other substances 
between the blood and surrounding tissues.   
In addition to carrying oxygenated blood to the peripheral tissues, large arteries serve as a 
reservoir for high-pressure blood that is pulsated from the heart. Due to the elastic 
component of the medial layer of large arteries, they are able to stretch and store large 
volumes of blood from the heart. The large arteries then contract between heartbeats, 
allowing the blood to flow out. Small arteries have strong muscular walls, which permit 
powerful constriction when stimulated by factors such as levels of oxygen and carbon 
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dioxide. Thus, the small arteries are the site of resistance and are able to control blood 
flow to the capillaries in peripheral tissues. Capillaries are the primary component of the 
vasculature; in the peripheral tissues, there are nearly 10 billion capillaries. Capillaries 
are highly specialized to meet the functional needs of the tissues that they vascularize 
(discussed in detail in Chapter 1 “Microvasculature”).  
In addition to carrying deoxygenated blood back to the heart, the veins have many other 
important functions. Veins are considered blood reservoirs and are able to expand in 
order to store large volumes of blood. Due to the low blood pressure in veins, structural 
modifications in the veins are necessary to maintain that the rate of blood circulation to 
and from the heart is equivalent. One such modification is the venous valve, created by 
the tunica intima folds, which prevents reverse blood flow. Through the “venous pump,” 
veins drive blood forward through the vasculature. Further, veins help regulate cardiac 
output by limiting the amount of available blood for the heart to pump through the 
venous return.  
Veins are approximately eight times more distensible than arteries. Therefore, they are 
capable of holding a much larger volume of blood, storing nearly 65% of the total blood 
volume in the body, whereas arteries contain only 15% of the total blood volume. 
Capillaries hold an even smaller portion (5%) of the total blood volume and maintain the 
systemic circulation’s critical function of material exchange between the blood and 
tissues.  
Arteries are categorized as large, often referred to as elastic; medium or muscular; small, 
and arteriolar. Similarly, veins are categorized as large, medium, and venular. Arteries 
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and veins are comprised of three layers: tunica intima, tunica media, and tunica 
adventitia. The tunica intima is the inner layer of the vessel and is comprised of 
endothelial cells (ECs). The tunica media is the middle layer of the vessel, composed of 
smooth muscle cells (SMCs), and the least defined and outermost layer of the vessel, the 
tunica adventitia, is composed of connective tissue.  
In large arteries (diameter 1.5 cm), the tunica intima is formed by an endothelium lining 
with a basal lamina, an internal elastic membrane, and a subendothelial layer. The tunica 
media of the large arteries, the thickest layer, is comprised by elastic material with 
interceding layers of a SMCs, collagenous fibers, and extracellular matrix. The tunica 
adventitia, the outermost layer, is primarily composed of collagenous fibers, but also 
contains elastic fibers, fibroblasts, and macrophages. In large arteries, the tunica 
adventitia is fairly thin, and its width is less than half of the tunica media.  
Whereas the tunica intima of medium arteries (diameter 6.0 mm) is similar to that of 
large arteries, it differs in that it has only a sparse subendothelial layer. The tunica media 
of medium arteries resembles that of large arteries, but has little elastic material present. 
The tunica adventitia of the medium artery is primarily composed of collagenous fibers 
like large arteries, however it is much thicker, nearly as thick as the tunica media. In 
addition, the tunica adventitia of medium arteries has a small external elastic lamina.  
Though the tunica intima of the small artery (diameter 0.1-5 mm) has an internal elastic 
lamina, the arteriole (diameter 37.0 µm) does not always contain this lamina. The tunica 
media of the arteriole has one or two layers of SMCs, whereas small arteries can have up 
to eight layers of smooth muscle.      
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While the tunica intima, tunica media, and tunica adventitia layers are well characterized 
in the arteries, these layers are less defined in the veins. In the tunica intima of large veins 
(diameter 5.0 mm), the layers remain the same as in large arteries; however, it is difficult 
to determine whether the SMC border belongs to the tunica intima or tunica media. The 
layers of the tunica media of large veins remain similar to that of the large arteries with 
the addition of fibroblasts but are relatively thin by comparison. In large veins, the tunica 
adventitia is much thicker and contains bundles of SMCs. In comparison to large arteries, 
the tunica adventitia of large veins contains the same components, but does not include 
macrophages.  
The composition of the tunica intima in medium veins is basically the same as medium 
arteries except that the internal elastic membrane, when present, is much thinner. 
Compared to medium arteries, the tunica media of medium veins is thinner, and SMCs 
are arranged circumferentially. In the medium veins, the tunica media is normally thinner 
than the tunica adventitia.  
 
Microvasculature 
The microvasculature is comprised of three components: arterioles, capillaries, and 
venules. Here, I will focus on capillaries, which are classified as either continuous or 
fenestrated. The most distinguishable characteristic of most continuous capillaries is the 
pinocytotic vesicles, which allow transepithelial transport of small molecules (Figure 1). 
Continuous capillaries are so called because of the continuous lining of ECs, which are 
connected by a variety of junctions including gap junctions, tight junctions, and adherens 
junctions. The endothelium of fenestrated capillaries have fenestrae or pores 
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(approximately 80 to 100 nm diameter) (Figure 1). In some cases, these fenestra have a 
diaphragm that allows selective filtration of small molecules and proteins. Fenestrated 
capillaries are found in secretory and filtering organs such as the choroid plexus, 
choriocapillaris, and kidney, to name just a few.  
In addition, there is a third type of capillary called a sinusoid. Sinusoidal capillaries, the 
largest of the three types of capillaries, are a specialized subset of the fenestrated 
capillaries and are distinguished by larger fenestrae (30-40 µm) without diaphragms 
(Figure 1). The larger fenestrae and the incomplete basal lamina in the sinusoid 
capillaries permit the passage of blood cells and serum proteins (Figure 1). Sinusoidal 
capillaries are found in the bone marrow, lymph nodes and adrenal glands. Finally, there 
is a subset of sinusoid capillaries, termed discontinuous sinusoidal capillaries, which lack 
tight junctions and are found in the liver and spleen. 
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Figure 1. The Capillary.  
A) Continuous capillary with continuous lining of ECs featuring tight junctions with few 
pinocytotic vesicles. B) Fenestrated capillary with pores (fenestrae). C) Sinusoid capillary 
with larger fenestrae and an incomplete basement membrane. (Adapted from Marieb 
2004).  
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In 1885, Paul Ehrlich first demonstrated the existence of a blood brain barrier (BBB) 
when he injected dyes intravenously into the circulatory system of animals and found that 
they stained all organs except those in the central nervous system (CNS) (Ehrlich 1885). 
Ehrlich credited this phenomenon to a low affinity of the CNS for the dye (Ehrlich 1904). 
In 1913, Edwin Goldman, Ehrlich’s student, injected trypan blue directly into the 
cerebrospinal fluid of animals and was only able to observe staining in brain cells, 
suggesting a barrier between the CNS and blood (Goldman 1913). The BBB is a filtering 
mechanism between the brain and the blood (Wislocke 1969; Pollay 1980).  
Similar to the BBB, the blood retinal barrier (BRB) regulates permeability between the 
retina and the blood (Ashton 1965A and 1965B; Cuhna-Vaz 1976 and 1966). There were 
two initial reports on the existence of a BRB (Schnaudigel 1913; Palm 1947), as well as 
many early studies on the association of altered vascular permeability with retinal 
pathology (Cunha-Vaz 1966; Hanum 1938; Ballantyne 1946; Friedenwald 1950; Ashton 
1951; Ashton, 1963). Yet, the ophthalmic field did not accept the existence of the BRB 
until 1965 (Cuhna-Vaz 1966 and 1976). Ashton and Cunha-Vaz injected histamine and 
colloidal carbon into animals and found labeling in many vessels of the eye including the 
iris, conjunctiva, and large vessels of the choroid but not in retinal and cerebral vessels, 
indicating the presence of a BRB similar to the BBB (Ashton 1965A).    
The BBB and BRB share many features including extensive tight-junctions between ECs. 
The BBB and BRB allow the passage of necessary nutrients and gases while restricting 
passage of hydrophobic and potentially toxic molecules from the choroid to the brain and 
retina, respectively (Shakib 1966; Pollay 1980). Tight-junctions in the BBB and BRB 
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differ from junctions in continuous capillaries in other organs, because they develop as a 
band, sealing any gaps between ECs (Shakib 1966; Cuhna-Vaz 1976; Pollay 1980).  
The breakdown of the BRB can be examined by fluorescein angiography (FA) and 
vitreous fluorometery (Cuhna-Vaz 1967, 1975, 1976, and 2004). Using these techniques, 
clinicians can identify functional changes prior to the appearance of pathological events 
(Cuhna-Vaz 1976). Of note, an increase in permeability of the BRB is an early change in 
the pathogenesis of diabetic retinopathy (DR) (Ashton 1965A; Cuhna-Vaz 1967 and 
1975; Norton 1967). 
 
The Pericyte  
Eberth and Rouget first observed the association of the perivascular cell with capillaries 
more than 140 years ago (Eberth 1871; Rouget 1873 and 1879). The pericyte has lengthy 
processes that stretch along the abluminal side of the capillary (Figure 2, Shepro 1993), 
the number and length of which differ among various microvascular beds. Secondary 
processes of pericytes, perpendicular to the primary processes, partially enclose the 
capillary (Figure 2, Shepro 1993). In 1923, Zimmerman coined the term “pericyte” for 
these perivascular cells (Zimmerman 1923); however the name for the pericyte, also 
referred to as a adventitial cell (Eberth 1871; Rouget 1873 and 1879), Rouget cell 
(Vimtrup 1922; Speiser 1968), intramural pericyte (Speiser 1968), mural cell (Kuwabara 
and Cogan 1963; Cogan and Kuwabara 1967), and pericapillary cell (Battig 1961), was 
debated throughout the 1960’s (Ashton 1966). The current definition of the pericyte, a 
cell embedded within the vascular basement membrane (BM), originated from electron 
microscopic analysis of capillaries (for a review, see Sims 1986).  
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Figure 2. Pericyte Anatomy.  
A) Mural cells in the microvasculature from arteriole to venule. Vascular SMCs 
circumferentially cover the arteriole and precapillary arteriole with few processes. 
Pericytes are present in the capillaries and have a rounded body with lengthy primary 
processes that are parallel to the vessel and secondary processes that are perpendicular to 
the vessel, enveloping the endothelium. Flattened mural cells wrap circularly around 
postcapillary venules with several thin processes, whereas the stellate shaped vascular 
SMCs with many processes in the venules do not. B) Pericyte-EC interactions in an 
ultrastructure schematic. Pericytes (P) and ECs (E) are separated by the BM, but still 
maintain physical contact through peg-and-socket arrangements and adhesion plaques. 
(Armulik 2011)  
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The BM is located on the abluminal side of the endothelium and is comprised of a 
protein-polysaccharide-rich layer and separates the EC from the pericyte. Interestingly, 
the subendothelial basement membrane (EBM) often has areas of discontinuity that allow 
the processes of ECs to directly contact the pericytes (arrows, Figure 3, Carlson 1989). 
The invagination of the processes of either ECs or pericytes into the membrane is called a 
peg-and-socket arrangement (Figure 4, Tilton 1979A; Cuevas 1984; Carlson 1989; 
Armulik 2005). This arrangement contains tight and gap junctions (Tilton 1979A; Cuevas 
1984; Carlson 1989; Armulik 2005). ECs and pericytes can also interact through adhering 
plaques (Carlson 1989). Whereas, a majority of EC-pericyte interactions occur through 
peg-and-socket arrangements and adhering plaques, some ECs and pericytes 
communicate as a result of spatial proximity (~2 nm), which likely makes the exchange 
of diffusible factors (i.e. juxtacrine communications) more effective (Carlson 1989).   
Pathological conditions are associated with changes in the BM. For example, in diabetes, 
the capillary BM dramatically thickens due to an increase in collagen type IV and laminin 
production (Ross 1989). Interestingly, there is a concomitant increase in permeability, 
though it is unclear if both changes occur in the same capillary.  
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Figure 3. Pericyte-EC interactions.  
Subendothelial basement membrane (EBM) discontinuities (arrows) allow EC processes 
to contact pericytes (P) in a human retinal capillary cross-section imaged by transmission 
electron microscopy. Intercellular junctions of neighboring ECs (J). Magnification 
x21,000. (Adapted from Carlson 1989).  
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Figure 4. Peg-and-socket arrangement between pericyte and EC. 
EC process (arrow) stretching through the subendothelial basement membrane (EBM) to 
interact with the pericyte (P), creating a peg-and-socket arrangement (bracket) in a 
human retinal capillary imaged by transmission electron microscopy. Magnification 
x41,000 (Adapted from Carlson 1989).  
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Pericyte abundance varies significantly by tissue. Capillaries of the CNS possess the 
highest EC to pericyte ratio of all tissues at a ratio of 1:1 in human retinas and a range of 
5:1-3:1 in the human brain (Speiser 1968; Armulik 2011; Duh 2008). This contrasts with 
an EC to pericyte ratio is 10:1 in human cardiac muscle and lungs (Armulik 2011; Duh 
2008; Shepro 1993). The pericyte density in human skeletal muscle is not agreed upon, as 
there are studies claiming as many as 100 ECs per pericyte and as few as 10 ECs per 
pericyte (Armulik 2011; Duh 2008; Shepro 1993; Tilton 1979B).  
Currently, there are no specific molecular markers for pan-pericytes. Instead, a number of 
molecular markers are used to identify pericytes that vary on several factors including 
species, vessel type, developmental or angiogenic stage, tissue specificity, and pathology. 
Alpha-smooth muscle actin (α-actin), desmin, and regulator of G protein signaling 5 
(RGS-5) are all intracellular protein markers for pericytes (Armulik 2005; Diaz-Flores 
2009; Herman and D’Amore 1985; DeNofrio 1989; Fujimoto 1987; Nehls 1992; 
Bondjers 2003; Cho 2003). The cytoskeleton protein, α-actin, stains pericyte 
microfilament bundles, SMCs, myoepithelium, and myofibroblasts (Skalli 1989; Darby 
1990; Armulik 2011). Desmin, a type III intermediate protein that labels pericytes, is also 
a marker for mature cardiac, skeletal, and SMCs (Nehls 1992; Bergers 2005; Armulik 
2011). Although utilized less often than α-actin and desmin, the GTPase-activating 
protein, RGS-5, is also a marker for pericytes and vascular SMCs (Bonjers 2003; Cho 
2003; Bergers 2005; Armulik 2011). Cell surface molecular markers for pericytes include 
neuron-glial 2 (NG2), platelet-derived growth factor receptor beta (PDGFRβ), and 
vascular cell adherence molecule-1 (VCAM-1) (Schlingemann 1990; Lindahl 1997; 
Carter 2001; Ozerdem 2001; Diaz-Flores 2009; Armulik 2011). In addition to being a 
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marker for pericytes, the chondroitin sulfate proteoglycan, NG2, is also expressed in 
vascular SMCs, developing cartilage, muscle, bone, and other cell types (Schlingemann 
1990; Ozerdem 2001; Huang 2010). The tyrosine-kinase receptor, PDGFRβ is expressed 
not only in pericytes, but also in developmental interstitial mesenchymal cells, 
myofibroblasts, smooth muscle, and some CNS neuronal cells (Lindahl 1997; Winkler 
2010; Armulik 2011). Since VCAM-1 is expressed in both pericytes and ECs, it is not 
used as frequently as the other cell surface proteins markers (Carter 2001; Diaz-Flores 
2009).  
Prior to the development of transgenic mouse technology, studies to elucidate the 
functional role of the pericytes used in vitro systems. Methods to culture large vessel ECs 
were developed in the 1970’s, while protocols to isolate microvascular ECs and pericytes 
were not developed until a decade later (Jaffe 1973; Gimbron 1974; Gitlin 1983).  
Pericytes and ECs are in close proximity in vivo and their cell-cell interactions are 
important to many aspects of microvasculature development, function and stability. 
Insight into the nature and the role of cellular crosstalk between EC and pericytes has 
been obtained by coculturing the cells. A number of systems have been developed and 
are reviewed here because results obtained in these systems are relevant to the findings in 
this thesis.  
The quickest and most straightforward method of examining pericyte-EC interactions is 
through direct contact two-dimensional coculture (Olridge and D’Amore 1987; Bryan 
and D’Amore 2008). For this purpose, the cells can be directly cultured in the same dish. 
Variables such as the effect of cell ratios can be examined using this system allowing 
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cells to physically interact. Therefore, it is difficult to determine if observed effects are 
due to the cells contact and/or to diffusible molecules that might be released into the 
medium. To remove the variable of cell contact, pericytes and ECs can be cocultured 
using transwells to prevent direct contact. The under agarose assay is an alternate 
technique for studying pericyte-endothelial interactions without direct contact (Bryan and 
D’Amore 2008). In this assay, the cells are plated into wells created in agarose and the 
effect of one cell type on the other can be examined. Growth factors, neutralizing antisera 
or other agents can be added to the agarose to examine their effects on the cells’ 
interactions.  
Whereas two dimensional cocultures described above have been utilized to study basic 
pericyte-EC migration and proliferation, development of three dimensional coculture 
systems has allowed further elucidation of the interactions between pericytes in a model 
that is more physiologically relevant. Thus, culturing the cells on or in collagen or 
matrigel BM creates an environment more similar to what is found in vivo (Darland and 
D’Amore 2001; Bryan and D’Amore 2008). Under these conditions, pericytes and ECs 
are able to form vessels with EC forming the lumen and the pericytes abluminally 
associated. Such models have permitted investigation into more complex aspects of 
morphogenesis such as lumen formation, matrix production and vessel regression 
(Hirschi 1998; Bryan and D’Amore 2001). 
 
Function of the pericyte  
Whereas early studies hypothesized the functional role of pericytes, the isolation of 
bovine retinal pericytes (BRPs) for in vitro studies (described in detail in Chapter 1 
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“Pericytes,” Gitlin and D’Amore 1983) created an avenue for conclusive experimental 
data illuminating pericyte function. Outlined below are the functional roles of the 
pericytes in capillary contractility, vessel stabilization, wound healing, and their potential 
as stem cells.   
Contractility  
Since their identification, it has been suggested that pericytes have contractile capacity 
and are involved in regulating capillary blood flow (Rouget 1873 and 1879; Vimtrup 
1922; Zimmerman 1923; Dore 1923; Krogh 1929; Kuwabara and Cogan 1963; Cogan 
and Kuwabara 1967; Shepro 1993). The location and morphology of pericytes 
corroborate this idea, since pericyte processes envelope ECs (Shepro 1993). Additionally, 
pericytes express contractile proteins such as α-actin, tropomyosin, myosin, and calponin 
(Joyce 1984, 1985A, and 1985B; Herman and D’Amore 1985; DeNofrio 1989; Diaz-
Flores 2009).  
Several in vitro studies have demonstrated a contractile role for pericytes. In the silicone 
rubber assay, vasoactive agents are added to cultured BRPs and the silicone wrinkles 
when pericytes constrict (Harris 1980; Kelley 1987 and 1988; Hamilton 2010). For 
example, it was demonstrated that pericytes contract in the presence of particular 
biogenic amines found in blood plasma, such as histamine and serotonin (Kelley 1988). 
Also, using the silicone rubber assay, endothelin-1 and thromboxane A2, EC-derived 
vasoconstriction agents, were shown to cause pericyte contraction, whereas prostaglandin 
I2 and nitric oxide (NO), EC-derived vasodilators, were shown to cause pericyte 
relaxation (Dodge 1991; Haefiger 1994). In addition, angiotensin II caused pericyte 
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contraction after pre-relaxation in the in vitro silicone rubber assay (Matsugi 1997). 
Adenosine, a potent vasodilator that accumulates in hypoxic and ischemic conditions, 
also causes pericyte relaxation in vitro (Matsugi 1997). Interestingly, pericyte 
contractility is inhibited by high glucose in the silicone rubber assay, which has 
implications for blood flow in early DR (Gillies and 1993).  
Moreover, pericyte contractility has also been shown in vivo, in situ, and ex vivo. In a 
study of capillaries from rat hearts and hindlimb skeletal muscle, perfusion with 
angiotensin II, norepinephrine, or vasopressin, vasoconstriction agents, each 
demonstrated pericyte contractility in the hindlimb skeletal muscle (Tilton 1979B). 
Additionally, Peppiatt et al found that pericytes constrict in response to gamma-
aminobutryic acid (GABA) antagonists in superfused rat retinas, and pericytes relax 
when treated with glutamate in superfused cerebral capillaries, demonstrating a role for 
neurotransmitters in pericyte tone (Peppiatt 2007).  
A number of studies outline an important role for intercellular calcium levels in 
modulating pericyte contractility (Sakagami 1999, 2001A, and 2001B; Sugiyama 2005; 
Peppiatt 2007; Hamilton 2010). Using perforated-patch conﬁguration of the patch–clamp 
technique, isolated rat retina capillaries were exposed to platelet-derived growth factor 
(PDGF)-BB, resulting in pericyte contraction and increased levels of calcium (Sakagami 
2001B). Conversely, in chemically induced ischemic conditions, pericytes in isolated rat 
retinal capillaries were shown to relax and calcium levels decreased in the presence of 
PDGF-BB (Sakagami 2001B). Further, electrically stimulated isolated rat retinal 
capillary pericytes constrict, however when extracellular calcium was removed, they 
relax, suggesting a direct role of calcium in pericyte contractility (Peppiatt 2006). 
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Pericytes express contractile proteins and have been shown by many techniques (outlined 
above) to contract in the presence of vasoconstriction agents and relax in the presence of 
vasodilators. In addition, a link between calcium levels and pericyte contractility has been 
elucidated. The vasoactive molecules discussed above are derived from ECs, glial cells, 
neurons, and metabolic factors. While it is clear that the current data support a contractile 
role for pericytes, further elucidation of the mechanism by which these other cell types 
and metabolic factors provide stimulants to the pericytes for contraction is required.  
Vessel Stability 
Mechanistically, the association of pericytes with ECs leads to the deposition of the BM 
and inhibition of both EC and pericyte migration and proliferation (Olridge and D’Amore 
1987; Sato and Rifkin 1989; Stratman 2009 and 2010), which are all hallmarks of vessel 
maturation. How pericytes contribute to vascular stability in adult vessels has begun to be 
elucidated. Relevant mechanisms may include pericyte regulation of EC-gene expression, 
pericyte BM deposition, and/or pericyte recruitment and integration into the vascular 
wall. Pericyte-EC interactions mediate several signaling pathways associated with vessel 
stability, including PDGF-B/PDGFRβ, TGFβ, and Angiopetin-1/TIE2.  
Pericytes express PDGFRβ, the receptor for PDGF-B, a protein secreted by proliferating 
ECs (Armulik 2011). Mice with targeted disruption of Pdgfrb or Pdgfb developmentally 
lack pericytes, which leads to vascular dysfunction and embryonic lethality (Leveen 
1994; Soriano 1994). In addition to pericyte loss, PDGF-B and PDGFRβ knockout 
models have abnormal EC ultrastructure and develop microangiopathies similar to those 
found in DR, including microaneurysms and leakage (Hellstrom 2001). During 
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angiogenesis, PDGF-B is upregulated in tip cells causing pericytes to be drawn 
immediately to the developing angiogenic sprouts (Gerhardt 2002). Thus, PDGFRβ and 
PDGF-B are essential for the recruitment of pericytes during angiogenesis and vessel 
stability.  
Although a majority of studies have focused on the developmental role of PDGFRβ and 
PDGF-B in pericytes, there have been recent reports on postnatal phenotypes. To 
generate postnatally viable animal models, PDGF-B cannot be deleted systemically. 
Therefore, PDGFB +/- mice and mice with an EC-specific conditional knockout of 
PDGF-B were created to study the effects of PDGF-B loss on pericytes (Enge 2002; 
Hammes 2002; Djarnegard 2003). In these models, pericyte loss occurs, but the degree of 
impact is variable (Enge 2002; Hammes 2002; Djarnegard 2003). PDGFB +/- mice were 
reported to have approximately 30% decrease in pericytes and a slight increase in 
acellular capillaries (Hammes 2002). Mice with EC-specific conditional knockout of 
PDGF-B exhibit microaneurysms and increased microvascular regression, when there is 
>50% pericyte coverage (Enge 2002; Djarnegard 2003). In addition, PDGF-B retention 
motif knockout mice displayed increased permeability when intravenously injected with 
molecular tracers and showed decreased CD71 expression, a known BBB marker, further 
elucidating a role for pericytes in barrier function (Armulik 2010). Loss of pericytes in 
PDGF-B mutants leads to a number of vascular dysfunctions, including acellular 
capillaries, microaneurysms, microvascular regression, and leakage, which are all 
symptomatic of vessel destabilization. Therefore, PDGF-B is necessary for vascular 
integrity.  
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Pericytes and ECs express transforming growth factor-β (TGFβ), as well as TGFβ 
receptors (Gaengel 2009). Thus, the elucidation of TGFβ signaling in either cell type is 
extremely complex (Gaengel 2009). To understand the broader role of TGFβ signaling, 
several knockout models of TGFβ/TGFβ receptors have been developed (tgfb1, alk5, 
tgbr2, eng, and smad5), most of which are embryonic lethal due to major abnormalities in 
the vasculature (Dickson 1995; Chang 1999; Yang 1999; Li 1999; Larsson 2001); half of 
the tgfb1 knockout mice survive for approximately two weeks, while the other half are 
embryonic lethal (Dickson 1995). Mice deficient in TGFβ type I receptor, also referred to 
as Alk-5, and endoglin, a TGFβ binding protein, lack SMC investment and formation, 
respectively (Li 1999; Larsson 2001).  
In addition, cell-cell interactions between pericytes and ECs are important for TGFβ 
signaling. For example, it has been demonstrated that pericyte-EC cocultures activate 
latent TGF-β1 and that contact between the cells is necessary (Antonelli-Orlidge 1989; 
Sato and Rifkin 1989). Distinct TGFβ type I receptors, activin receptor-like kinase (Alk)-
1 and Alk-5, mediate TGF-β signaling (Gaengel 2009; Goumans 2002). In vitro studies 
showed that Alk-1 and Alk-5 have opposite effects on EC migration and proliferation 
(Goumans 2002). Further, in vivo studies targeting EC specific knockdown of Alk-5 have 
demonstrated a reduction in EC secretion of TGF-β1, which results in reduced signaling 
of TGFβ/Alk5 in pericytes (Carvalho 2004). Together, these data suggest an important 
and linked role for TGFβ signaling in pericytes and ECs. 
Many reports have suggested the importance of angiopoietin-1/Tie2 signaling in pericyte-
EC interactions and vascular development. EC express tie2, and angiopoietin-1 is 
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produced by the pericytes (Sato 1995; Davis 1996; Sundberg 2002; Armulik 2005). Ang1 
and tie2 knockout mice are pericyte deficient and suffer from cardiovascular failure at 
mid-gestation (Suri 1996; Patan 1998). Intravitreal injection of angiopoeitin-1 to a model 
in which retinal pericyte deficiency was induced with an anti-PDGFRβ antibody, was 
shown to rescue high-order architecture of the developing vasculature (Uemura 2002). 
Thus, angiopoeitin-1 in pericytes has a crucial role in vascular stability and maturation.  
Pericytes as stem cells  
The concept that pericytes are, in fact, mesenchymal stem cells (MSCs) has long been a 
topic of discussion and continues to be so today (Movat and Fernando 1964; Maxwell 
and Kruger 1965; Meyrick and Reid 1979; Shi 2003; Schwab and Gargett 2007; 
Zannetitino 2008; Corselli 2010). In an early investigation, pericytes were shown to 
differentiate into SMCs when cultured under hypoxic conditions (Meryick and Reid 
1979). Evidence that pericytes share many markers with SMCs including the contractile 
proteins (α-actin, myosin, and cyclic GMP-dependent protein kinase) also suggests a 
conceivable role of pericytes as stem cells (Herman and D’Amore 1985; Joyce 1985A 
and 1985B; Sims 1986). In addition, it has also been shown that, in vitro, ECs induce 
multipotent mesenchymal 10T1/2 cells to differentiate into mural cells through PDGF-
BB, which further corroborates the concept of stem cell-like properties in pericytes 
(Hirschi 1998; Hirschi 1999).  
Pericytes have also been reported to differentiate into a number of cell types including 
phagocytes, adipocytes, SMCs, osteoblasts, granulocytes, and chondrocytes (Movat and 
Fernando 1964; Maxwell and Kruger 1965; Schwab and Gargett 2007; Corselli 2010; 
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Farrington-Rock 2004; Paquet-Fifield 2009; Mills 2013). For example, in a study by 
Farrington-Rock and colleagues, BRPs cultured as pellets in chondrogenic medium for 
three weeks expressed Sox9, aggrecan, and collagen II, which are chondrocyte markers, 
whereas ECs cultured under the same conditions did not (Farrington-Rock 2004). In 
addition, BRPs cultured in 20% rabbit serum for 2 weeks expressed peroxisome 
proliferator–activated receptor-γ2, an adipose marker. Further, when BRPs were 
harvested in diffusion chambers in nude mice for 56 days, mineralized cartilage and 
adipose-like cells (Farrington-Rock 2004). In another study, human endometrium stromal 
cells co-expressing CD146 and PDGFRβ, pericyte markers, were cultured with 
myogenic, adipogenic, osteogenic, and chondrogenic induction media for four weeks, and 
subsequently expressed markers of SMCs, osteoblasts, adipocytes, and chrondocytes, 
respectively (Schwab 2007). Taken together, these reports strongly implicate a functional 
role for pericytes as stem cells.  
Wound healing  
The role of the pericyte in wound healing was first noted in a wounding rabbit model in 
1940 by Clark and Clark and later substantiated by Cliff in 1963 (Clark and Clark 1940; 
Cliff 1963). New capillaries sprout after injury occurs, and as the development of these 
new capillaries progress, pericytes begin to attach to the proliferating and maturing ECs 
(Cliff 1963; Crocker 1970). Subsequent studies showed that the cessation of EC 
proliferation was marked by the arrival of the pericyte, leading to the suggestion that 
pericytes have a regulatory role in capillary proliferation during wound healing (Crocker 
1970).    
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A recent study demonstrated that the prevalence of MSCs increases with injury (Mills 
2013). Conversely, many reports have treated wounding models with MSCs and 
demonstrated improved healing (Nakawaga 2005; Mansilla 2006; Wu 2007; Falanga 
2007). MSCs are thus an obvious target for therapeutics in wound healing, but the 
isolation and purification of MSCs for human therapeutic use is complex and 
challenging. Hence, the use of pericytes in the place of MSCs may have potential. 
 
Diabetic Retinopathy  
Diabetes is a growing epidemic that affects 24.4 million people in the U.S. and 382 
million people worldwide (International Diabetes Federation 2013). A chronic metabolic 
disease, diabetes is characterized by little to no insulin production by the pancreas (type 
I) or insulin resistance (type II) (International Diabetes Federation 2013; American 
Diabetes Association 2010). Ninety to ninety-five percent of diabetes cases in the US are 
type II (International Diabetes Federation 2013; American Diabetes Association 2010). 
Type II diabetics do not produce enough insulin, or their body does not recognize the 
insulin they do produce, resulting in a surplus of glucose (International Diabetes 
Federation 2013; American Diabetes Association 2010). Diabetic patients are 
hyperglycemic, and therefore have excess glucose in the bloodstream, which can damage 
blood vessels and nerves (International Diabetes Federation 2013; American Diabetes 
Association 2010). 
Diabetics encounter many complications including macrovascular and microvascular 
diseases (Fowler 2008; Cade 2008; International Diabetes Federation 2013; American 
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Diabetes Association 2010). Cardiovascular disease (CVD) is the major cause of death in 
diabetics, who are four times more likely to develop CVD (Fowler 2008; Cade 2008). 
The microvascular complications include nephropathy, neuropathy, and diabetic 
retinopathy (DR) (Fowler 2008; Cade 2008). Nephropathy occurs in 35% of diabetic 
patients and eventually progresses to renal failure in these patients (Fowler 2008; Cade 
2008; Tesfaye 2010). Neuropathy is seen in nearly half of all diabetic patients and often 
leads to lower limb amputations (Fowler 2008; Cade 2008; Yau 2012). DR is present to 
some extent in almost all diabetics 30 years after diagnosis and can lead to partial or total 
vision loss (Roy 2004; Cade 2008; Cheung 2010; Yau 2012).  
DR is among the most common complication of both type 1 and type 2 diabetes, and a 
leading cause of permanent vision loss worldwide (Roy 2004; Cheung 2010; Yau 2012). 
There are two stages of DR: non-proliferative (NPDR) and proliferative (PDR). The early 
stage of DR, referred to as NPDR or background retinopathy, is characterized by 
morphological and functional abnormalities in glial and neuronal cells as well as 
degenerative changes in the choriocapillaris and retinal vessels (Cogan 1964; Gerhardt 
2003; Antonetti 2012). These include microaneurysms, capillary swelling, and 
hemorrhaging (Cogan 1964; Gerhardt 2003; Antonetti 2012). As the disease progresses, 
vascular degeneration leads to ischemia, which induces the expression of vascular 
endothelial growth factor (VEGF) and retinal angiogenesis, a process referred to as PDR 
(Antonetti 2012; Taylor 1970; Sapieha 2010). PDR is associated with new vessel 
formation, fibroblast proliferation, and vitreous hemorrhaging, and both NPDR and PDR 
are associated with macular edema (Gerhardt 2003).   
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Clinical and experimental data provide strong support for the concept that the 
microvascular complications of DR are due in large part to hyperglycemia (The diabetes 
control and complications trial 2000). There is also mounting evidence that inflammation 
plays a key role in the pathophysiology of DR (Tang and Kern 2011). For example, in 
vitro studies have shown that high glucose causes increased expression of TNFα, TNFβ, 
interleukin (IL)-1β, nuclear factor (NF)-κB, intercellular adhesion molecule (ICAM)-1, 
and VEGF (Kowluru 2010).  
In streptozotocin induced diabetic (STZ) and galactosemia mice, systemic inhibition of 
caspase-1 using minocycline decreased retina degeneration including production of 
acellular capillaries (Vincent and Mohr 2007); caspase-1 is the enzyme that generates 
mature IL-1β. In addition, diabetic (STZ-induced) mice were systemically treated with 
dehydroxymethylepoxyquinomicin, a NF-κB inhibitor, which decreased retinal 
leukostasis and ICAM-1 and VEGF expression compared to diabetic controls (Nagai 
2007). Similarly, in ICAM-1 null mice with diabetes (STZ-induced) or hyperglycemia 
(galactosemia), hallmark characteristics of DR were decreased including pericyte loss, 
acellular capillaries, and leakage (Joussen 2004). Intravitreal injection of anti-
VEGF164(165) aptamer in diabetic (STZ-induced) mice at short (three weeks) and long 
(two months) time points demonstrated significant decrease in retinal leukostasis and 
permeability (Ishida 2003). Further, it has been clearly demonstrated that hypoxia, 
leading to the upregulation of VEGF, is crucial for the transition from DR to PDR 
(Adamis 1994; Aiello 1994; Miller 1997; Joussen 2004; Antonetti 2006; Avery 2006; 
Mason 2006; Gologorsky 2012). 
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In 1961, Cogan first reported the loss of retinal microvascular pericytes, referred to as 
pericyte dropout, in NPDR (Cogan 1961) and pericyte dropout is the first morphological 
change observed in DR. Quantification of pericyte dropout in DR revealed a ratio of ECs 
to pericytes in normal (1:1) versus diabetic (4:1) retinal microvasculature (Speiser 1968). 
Pericyte dropout occurs temporally prior to the development of microangiopathies such 
as microaneurysms, acellular capillaries (Cogan 1961; Engerman 1989) vessel tortuosity, 
hyperpermeability, and capillary non-perfusion (Cogan and Kuwabara 1976; Klein 
1984A and 1984B; Hammes 2002; Sasongko 2011).  
Many reports using diabetic animal models support a link between pericyte dropout and 
microangiopathy, however in these studies causality is inconclusive due to the 
complexity of obese and hyperglycemic models (Robinson 2012). DR has been studied in 
several mouse models including STZ induced diabetes, non-obese diabetic (NOD), db/db, 
Ins2Akita (Akita), Akimba, and the galactosemia model (Table 1, Robinson 2012). 
Although none of these models progress to PDR, they do develop some of the hallmarks 
of background or NPDR including microaneurysms, microvascular permeability and 
acellular capillaries (Table 1, Robinson 2012).  
The goal of this work was to assess the precise role of the pericyte in retinal 
microangiopathy, wherein I hypothesized that pericyte loss is sufficient to cause 
microangiopathies in the adult microvasculature. To eliminate the variables encountered 
in the various models of diabetes, we have developed a mouse model of inducible mural 
cell loss. This model has allowed us to examine the effects of pericyte loss on the 
integrity and function of the adult retinal microvasculature.  
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Table 1. Mouse models of DR. Summary of retinal lesions found in mouse models of 
DR. (Adapted from Robinson 2012) 
  
                     Diabetic Retinopathy Mouse Model 
Retinal Lesions 
 
STZ db/db NOD Akita Akimba Galactosemia 
Microaneurysms 
     
     +          + 
Acellular capillaries 
 
 +   + 
 
  + 
 
         + 
Pericyte loss 
 
  +    + 
   
         + 
Venous bleeding 
     
    + 
 Hemorrhages 
     
     + 
 BM thickening 
  
  + 
   
        + 
Tortuosity 
     
    + 
 Retinal edema 
     
     + 
 Retinal thinning 
 
 + 
  
  + 
  Apoptosis of vascular cells   + 
 
 + 
   Ganglion cell loss 
 
  + 
  
  + 
  BRB breakdown   + 
    Capillary dropout 
     
    + 
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CHAPTER 2 
CHARACTERIZING AN INDUCIBLE MOUSE MODEL  
OF MURAL CELL DEATH 
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AIM  
To evaluate the role of pericyte loss in the adult retinal microvasculature using a mouse 
model of inducible mural cell dropout.  
 
RATIONALE 
Pericyte loss, commonly referred to as pericyte “drop-out,” was first described in human 
background, or non-proliferative, DR by Cogan in 1967 and is understood to be an early 
event in the development of DR (Cogan and Kuwabara 1967). The loss of pericytes 
precedes the development of other microangiopathies including microaneurysms, 
acellular capillaries (Cogan and Kuwabara 1961; Engerman 1989) vessel tortuosity, 
hyperpermeability, and capillary non-perfusion (Cogan and Kuwabara 1961; Klein 
1984A and 1984B; Hammes 2002; Sasongko 2011). The temporal association between 
pericyte loss and microangiopathy is also supported by examination of several animal 
models of diabetes (Robinson 2012) where analysis of their causality is confounded by 
the effects of comorbidities and obesity commonly found in these models.  
Similarly, in the PDGF-B/PDGFRβ knockout mice, the developmental absence of 
pericytes is associated with microaneurysms and embryonic lethality (Lindahl 1997; 
Armulik 2011). Mice with conditional ablation of PDGF-B in EC (Enge 2002), PDGF-B 
heterozygosity, or expressing PDGF-B hypomorphic mutants (Bell 2010; Armulik 2010) 
are all postnatally viable and show various degrees of pericyte deficiency and other 
microangiopathies. Yet, in each case, the postnatal phenotypes cannot be definitively 
distinguished from other developmental abnormalities. Thus, experimental demonstration 
of a link between pericyte loss and microvascular degeneration in the retina is lacking.  
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I aimed to develop a model that would allow investigation of the role of the pericyte in 
the development of retinal microangiopathies in non-diabetic mice. I accomplished this 
by using mice that would allow the direct induction of mural cell death in adult mice. 
This approach allowed me to examine the acute effects of pericyte loss on the integrity 
and function of the adult retinal microvasculature. 
 
RESULTS 
Mouse model of inducible mural cell loss 
I first sought to establish a model of inducible mural cell death by breeding mice carrying 
a floxed allele of the iDTR, which has been shown to render mouse tissues susceptible to 
diphtheria toxin (DT) (Brochschnieder 2004; Buch 2005), with mice expressing 
tamoxifen-inducible Cre recombinase under the control of the SMMHC promoter (M-
Cre), which would lead to mural cell specific death (Wirth 2008). After generating the 
iDTR; M-Cre mouse line, I established a timeline for induction of mural cell death. Since 
the goal is to examine the effect of pericyte loss in the adult, M-Cre and iDTR; M-Cre 
mice were injected intraperitoneally (IP) with tamoxifen (500 ng in 225 µl corn oil) at 
adult age (eight-weeks old). DT (1 µg in saline over two days) was administered eight- to 
10-weeks after tamoxifen (Figure 5). This design allowed examination of the effects of 
DT-induced cell death in retinas from adult (16-18-weeks old) mice with spatial and 
temporal resolution (Figure 5). 
To validate that the simian DTR is activated in the iDTR; M-Cre mice, vascularized 
tissues from untreated and tamoxifen treated iDTR; M-Cre mice were analyzed for the 
expression of DTR mRNA. As expected, DTR expression was detected by qPCR in the 
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aorta and kidney of iDTR; M-Cre adult mice (10-weeks old mice, Figure 6) upon IP 
tamoxifen administration (Figure 5). Once it had been established that the DTR 
expression is induced in the presence of Cre, I wanted to validate that the M-Cre 
promoter was not leaky. To accomplish this, aorta-derived SMCs from iDTR; M-Cre 
mice were isolated and cultured then treated with vehicle (ethanol) or tamoxifen (1 µM in 
ethanol). Expression of the DTR was detected by qPCR in tamoxifen treated iDTR; M-
Cre aorta-derived SMCs with a 4.5-fold increase compared to vehicle (Figure 7).  
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Figure 5. Generation of a mouse model of inducible mural cell loss.  
Adult (eight-weeks old) M-Cre and iDTR; M-Cre mice were treated daily with tamoxifen 
(IP, 500 ng in 225 µl corn oil) for three days. Eight- to 10-weeks after tamoxifen 
treatment, mice were treated with DT (IP, 500 ng in 100 µl saline) for two consecutive 
days. Five days post-DT administration mice were euthanized and tissues were harvested 
for analysis.  
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Figure 6. DTR expression in vascularized tissues from iDTR. M-Cre mice.  
Tamoxifen was administered to eight-week-old iDTR. M-Cre mice; controls were mice 
of the same genotype that did not receive tamoxifen. Kidneys and aortas were collected 
from iDTR; M-Cre mice (10-weeks old) that had been treated with tamoxifen or control 
mice that had not been tamoxifen treated. mRNA was isolated by phenol chloroform 
extraction from whole tissues. Expression of the DTR was measured by quantitative PCR 
in the kidney and aorta. To calculate the fold-change using the standard 2-∆∆Ct formula, 
a Ct value of 35, corresponding to the lowest limit for detection, was used when signal 
was not detected for DTR. * P < 0.05, *** P < 0.001 
 
 
 
 
 
 
 
 
 
 
 
 
	   36	  
 
 
 
 
 
 
 
 
 
Figure 7. Expression of DTR in iDTR; M-Cre aorta-derived SMCs in vitro.  
Aortas were collected from untreated iDTR; M-Cre mice (10-weeks old). Using 
collagenase II (175 units/ml) and dissection, the tunica adventitia of the aortas was 
removed. Aortas were cut lengthwise to expose the ECs, which were manually removed 
by scraping, and the remaining tunica media layer of the aorta was cultured overnight in 
10% FBS in DMEM. A single cell suspension of aortic SMCs was created by further 
digesting the aorta with a collagenase II (175 units/ml) and elastase (0.5 mg/ml) mixture. 
iDTR; M-Cre aorta SMCs were treated with vehicle (ethanol) or tamoxifen (1 µM in 
ethanol) for 48 hours in 10% FBS DMEM. Total RNA was isolated using a RNeasy Kit 
(Qiagen). Expression of diphtheria toxin receptor (DTR) was measured by quantitative 
PCR. ** P < 0.01 
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The primary goal of this study is to establish a model of inducible mural cell dropout in a 
normal mouse. Thus, I wanted to validate that the treatments for induction in this mouse 
model did not influence major physiologic endpoints. To this end, blood was collected 
from M-Cre and iDTR; M-Cre mice by submandibular bleeding, and blood glucose levels 
were measured using a glucometer. There was no significant difference in blood glucose 
measurements post-tamoxifen or post-DT treatment (post-tamoxifen treatment: M-Cre – 
170.0 ± 14.0 mg/dL, iDTR; M-Cre – 185.5 ± 28.6 mg/dL; post-DT treatment: M-Cre – 
168.2 ± 14.8 mg/dL, iDTR; M-Cre – 176.7 ± 29.7 mg/dL, Figure 8A). Wild-type 
C57BL/6 male mice (nine- to 13-weeks old) have an average blood glucose 198 ± 13.6 
mg/dL, and therefore the mice in this study are within normal range (Shonfeld). In 
addition, plasma insulin levels in iDTR; M-Cre, DT-treated M-Cre, and DT-treated 
iDTR; M-Cre mice were measured post-mortem by ELISA. No significant differences 
were observed in blood plasma insulin levels (DT-treated M-Cre – 0.788 ± 0.299 ng/ml, 
iDTR; M-Cre – 1.171 ± 0.848 ng/ml, DT-treated iDTR; M-Cre – 0.452 ± 0.050 ng/ml, 
Figure 8B).  
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Figure 8. Glucose and insulin levels in iDTR; M-Cre mice.  
(A) Blood was collected from M-Cre and iDTR; M-Cre mice (n=6) by submandibular 
bleeding and levels of blood glucose were measured using a glucometer. Administration 
of tamoxifen or DT did not influence blood glucose levels in M-Cre or iDTR; M-Cre 
mice. (B) Blood plasma was collected post-mortem from M-Cre and iDTR; M-Cre mice 
(n=6) and plasma insulin levels were measured by ELISA. Plasma insulin levels were not 
significantly different among any of the groups.  
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Tamoxifen treatment was associated with a significant increase (P<0.05) in body weight 
in iDTR; M-Cre mice, whereas DT treatment was associated with a significant decrease 
(P<0.05) in body weight compared to tamoxifen and/or DT treatment of M-Cre mouse, 
which had no effect on body weight (no treatment: M-Cre – 25.0 ± 4.73 g, iDTR; M-Cre 
– 24.5 ± 1.64 g; tamoxifen treatment: M-Cre – 28.7 ± 2.58 g, iDTR; M-Cre – 29.7 ± 1.63 
g; DT treatment: M-Cre – 28.0 ± 1.67 g, iDTR; M-Cre – 25.8 ± 1.17 g, Figure 9A). 
Similarly, there was no difference in the weight of the kidney, brain, and heart (measured 
at sacrifice) among the groups (kidney: iDTR; M-Cre – 0.214 ± 0.021 mg, DT-treated M-
Cre – 0.193 ± 0.015 mg, DT-treated iDTR; M-Cre – 0.164 ± 0.017 mg; brain: iDTR; M-
Cre – 0.454 ± 0.017 mg, DT-treated M-Cre – 0.447 ± 0.021 mg, DT-treated iDTR; M-
Cre – 0.450 ± 0.023 mg; heart: iDTR; M-Cre – 0.188 ± 0.024 mg, DT-treated M-Cre – 
0.197 ± 0.059 mg, DT-treated iDTR; M-Cre – 0.169 ± 0.013 mg, Figure 9B). The weight 
of the liver was significantly different among the DT-treated iDTR; M-Cre mice and 
control groups (P<0.01) (liver: iDTR; M-Cre – 1.127 ± 0.140 mg, DT-treated M-Cre – 
1.110 ± 0.197 mg, DT-treated iDTR; M-Cre – 0.756 ± 0.074 mg, Figure 9B), which is 
likely due to a decrease in glycogen observed in DT-treated iDTR; M-Cre mice 
(Supplemental Figure 3).  
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Figure 9. Measurements of physiological functions in iDTR; M-Cre mice.  
(A) Body weights were measured in M-Cre mice (n=6) at eight-weeks of age (no 
treatment), 16-weeks of age (post-tamoxifen treatment), and 16-weeks plus 5 days (post-
DT treatment). The weights of iDTR; M-Cre mice varied significantly between 
treatments. (B) Organ weights were measured in M-Cre (+DT), iDTR; M-Cre (-DT) and 
iDTR; M-Cre (+DT) mice (n=6) at 16-18-weeks of age. The livers of DT treated iDTR; 
M-Cre mice were significantly decreased. No differences were observed in the weights of 
brains, hearts, and kidneys among the three groups. **P < 0.01, *** P < 0.001 
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Next, I sought to validate that DT treatment of iDTR; M-Cre mice that had been induced 
to express iDTR would lead to the death of mural cells (SMCs and pericytes). Whole 
retinal flat mounts were prepared and stained for alpha-smooth muscle actin (α-actin, 
green) to detect mural cells and terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL, red) to detect fragmented DNA indicative of apoptotic cells. 
Consistent with the expression pattern expected from the SMMHC promoter-Cre driver, 
TUNEL-positivity was observed in vascular smooth muscle cells on retinal arteries 
(Figure 10A & B). TUNEL-positive cells were identified as pericytes on the basis of their 
localization and their co-staining with α-actin antibodies (Figure 10C). TUNEL-positive 
cells were located at microvessel bifurcations and along the abluminal surface of the 
microvasculature, positions characteristic of pericyte localization (Figure 10C & 11). 
Apoptotic cells were detected in retinal flat mounts from iDTR; M-Cre animals but were 
largely absent from mice lacking the iDTR transgene (Figure 11).  
Following the demonstration of mural cell death in iDTR; M-Cre mice following the 
administration of DT, I sought to quantify the number of apoptotic cells present in the 
retina. Whole retinal flat mounts were prepared from DT-treated M-Cre and iDTR; M-
Cre mice and stained for isolectin B4 (green) to detect ECs and TUNEL (red) to detect 
cell death. More than 40 TUNEL-positive mural vascular cells per retina were observed 
five days after the first DT injection (Figure 12); these were often seen near vessels 
lacking mural cell investment (Figures 10 & 11), indicating that cell death was a dynamic 
process (TUNEL-positive cells/retina: DT-treated M-Cre – 5.67 ± 1.53 vs. DT-treated 
iDTR; M-Cre – 43.20 ± 5.23; P = 0.0018; Figure 12).  
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Figure 10. Mural cell apoptosis in an inducible mouse model of mural cell loss.    
Retinal flat mounts were stained for alpha smooth muscle actin (α-actin, green) to detect 
mural vascular cells (pericytes and smooth muscle cells) and for apoptotic cells using an 
in situ cell death detection kit (red). TUNEL-positive (A-B) SMCs (yellow arrows) and 
(C) pericytes (white arrow) as well as missing vascular smooth muscle cells (arrowheads) 
were observed in iDTR; M-Cre mice five days following DT injection. Dashed line 
represents location of optic nerve. Scale bar = 50 µm. 
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Figure 11. Characterization of inducible mouse model of mural cell loss. 
Retinal flat mounts were stained for isolectin B4 (green) to detect ECs and with TUNEL 
(using an in situ cell death detection kit, red) to detect apoptotic cells. TUNEL-positive 
cells were observed in iDTR; M-Cre mice five days following DT injection (arrow). 
Scale bar = 100 µm. 
 
 
 
 
	   44	  
 
 
 
 
 
 
 
 
Figure 12. Quantification of apoptotic cells in an inducible mouse model of mural 
cell loss. 
The number of apoptotic cells as quantified by counting the total number of TUNEL-
positive nuclei in retinal flat mounts stained for isolectin B4 and with TUNEL from M-
Cre (n=3) and iDTR; M-Cre (n=5) mice. Approximately 40 apoptotic cells per retina 
were observed in DT-treated iDTR; M-Cre mice and less than 6 apoptotic cells per retina 
were seen in DT-treated M-Cre. ** P < 0.01 
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Microangiopathy in mouse model of inducible mural cell death 
I sought to determine the relationship between pericyte loss and hallmark characteristics 
of DR, such as microaneurysms and vascular leakage (Cogan and Kuwabara 1967; Klein 
1984A and 1984B; Hammes 2002). To this end, whole retinal flat mounts were prepared 
from DT-treated M-Cre and iDTR; M-Cre mice and stained for isolectin B4 (green) to 
detect ECs and TUNEL (red). The total number of microaneurysms per retina was 
counted manually by visually assessing the fluorescent microscopy images. An average 
of three microaneurysms were observed per retina in iDTR; M-Cre mice, and these were 
often seen in capillaries in association with TUNEL-positive cells 
(microaneurysms/retina: DT-treated M-Cre – 0.33 ± 0.33 vs. DT-treated iDTR; M-Cre – 
3.20 ± 0.49; P = 0.0063; Figure 13). This observation indicates that microaneurysms 
appear acutely after pericyte death, considering that DNA fragmentation is a late-stage 
event during apoptosis (Collins 1997). To determine if pericyte loss had an effect on 
vascular leakage, I perfused mice with 50 mg/ml fluorescein dextran (2x106 mw) in 4% 
paraformaldehyde in PBS prior to flat mounting; high molecular weight dextran should 
not escape an intact blood retinal barrier. An average of six hyperpermeable areas, 
identified as regions of fluorescein-dextran leakage, were observed per retina in iDTR; 
M-Cre mice, indicating breakage of the BRB (hyperpermeable areas/retina: DT-treated 
M-Cre – 0.66 ± 0.33 vs. DT-treated iDTR; M-Cre – 7.00 ± 1.87; P = 0.0363; Figure 
14B). The number of leakage events was highly variable between mice but generally 
affected only the capillaries (Figure 14 and data not shown).  
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Figure 13. Pericyte loss in the retinal microvasculature is associated with the 
formation of microaneurysms. 
(A) Microaneurysms were observed in retinal flat mounts from iDTR; M-Cre 
(+tamoxifen, +DT) mice labeled with isolectin-B4 to detect EC (green) and TUNEL 
(red). (B) Microaneurysms were quantified by assessing fluorescence microscopy images 
of M-Cre (+tamoxifen, +DT, n=3) and iDTR; M-Cre (+tamoxifen, +DT, n=5) mice. (C) 
Microaneurysms in retinal elastase digests stained for periodic acid-Schiff (PAS) and 
counterstained with hematoxylin from an iDTR; M-Cre (+tamoxifen, +DT) mouse. Scale 
bars = 50 µm. ** P < 0.01 
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Figure 14. Increased microvascular permeability in retinal microvasculature of mice 
with inducible mural cell loss. 
(A) DT-treated M-Cre (left panel) and iDTR; M-Cre (right panel) mice were perfused 
with 50 mg/ml fluorescein dextran (2x106 mw) prior to retina imaging using fluorescence 
microscopy. Areas of vascular leakage (arrows) were observed in DT-treated iDTR; M-
Cre mice. (B) Hyperpermeable areas per retina were quantified in M-Cre (+tamoxifen, 
+DT, n=3) and iDTR; M-Cre (+tamoxifen, +DT, n=4) mice. Scale bar = 250 µm. * P < 
0.05 
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Quantification of pericyte loss 
TUNEL staining of retinal flat mounts yields a view of cell death occurring in a snapshot 
of time in the retinas of the mouse model of inducible mural cell loss. However, from the 
visualization of retinal flat mounts stained with α-actin and TUNEL (Figure 10), where 
there is already some mural cell loss (indicated by a lack of α-actin staining) and other 
mural cells are in the process of dying (indicated by TUNEL-positive cells), it is evident 
that the cell death process in this model is dynamic. Thus, I wanted to quantify the total 
loss of pericytes and ECs in the retinal microvasculature. The current standard in the field 
for pericyte and EC quantification is to isolate the retinal microvasculature by elastase 
digest and manually count the number of pericytes and ECs based on their size and 
morphology (Speiser 1968; Laver 1993; Kern and Engerman 1996; Hammes 1997; 
Zhang 2012). However, this standard is only applicable to rats, dogs, cats, primates, and 
humans and does not apply to mice, where distinguishing these cell types is less clear.  
Therefore, in collaboration with Wimasis Image Analysis (www.wimasis.com), I 
established a methodology for quantifying pericytes and ECs in the retinal 
microvasculature of mice using automated image analysis (for full details see Chapter 6). 
To quantify pericytes and ECs in mice, the retinal vasculatures were isolated by elastase 
digest and then analyzed using automated image analysis (Figures 15, 16, 25 & 26). This 
analysis revealed that five days after DT administration approximately 7-15% of 
pericytes were lost from the retinal microvasculatures from DT-treated iDTR; M-Cre 
mice compared to the M-Cre and iDTR; M-Cre controls, respectively (pericytes/mm: DT-
treated M-Cre – 8.647 ± 0.459, iDTR; M-Cre – 9.475 ± 0.490, DT-treated iDTR; M-Cre 
– 8.031 ± 0.302; Figure 16). This finding indicates that microangiopathy can be triggered 
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by the loss of a relatively small proportion of pericytes (Figures 15 & 16). Interestingly, 
but perhaps not surprisingly, the number of endothelial cells was also reduced in DT-
treated iDTR; M-Cre mice (8-9%, Figure 16), although this difference was not 
statistically significant, and no TUNEL-positive ECs were observed in the analysis.  
In light of the decrease in both pericytes and ECs in the mouse model of inducible mural 
cell loss, I hypothesized that these mice might also display acellular capillaries. Acellular 
capillaries have been defined as capillaries lacking nuclei along their length with a 
minimum of one-fourth the width of a normal capillary (Kern and Engerman 2001; 
Zheng and Kern 2004; Zheng and Berkowitz 2007; Howell and Kern 2013); this 
definition which leaves room for a broad interpretation. Thus, in collaboration with 
Wimasis Image Analysis, I developed an automated image analysis system for 
identifying acellular capillaries in retinal microvasculatures. Image analysis automation 
was used to define acellular capillaries as those lacking nuclei in a length greater than the 
average internuclei distance and being a minimum of one-fourth the width of a normal 
capillary (for full details see Chapter 6) (Kern and Engerman 1996; Kern and Engerman 
2001; Zheng and Kern 2004; Barber 2005; Zheng and Berkowitz 2007; Howell and Kern 
2013). This analysis revealed that DT-treated iDTR; M-Cre mice had approximately 
twice as many acellular capillaries per millimeter of capillary length as the control groups 
(acellular capillaries/mm capillary length: DT-treated M-Cre – 0.400 ± 0.147, iDTR; M-
Cre – 0.511 ± 0.114 DT-treated iDTR; M-Cre – 0.812 ± 0.062; P<0.05; Figures 17 & 18).  
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Figure 15. Retinal microvasculature of a mouse model of inducible mural cell loss.  
Vessels were digested from retinas using elastase and stained with periodic acid-Schiff 
(PAS) and hematoxylin. Elastase digested vasculature from iDTR; M-Cre (top left panel), 
DT-treated M-Cre (top right panel), and DT-treated iDTR; M-Cre (bottom panel) retinas 
showing pericytes (white arrowheads) and ECs (black arrows). Scale bars = 50 µm. 
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Figure 16. Loss of pericytes in retinal microvasculature of a model of inducible 
mural cell loss. 
(A) The number of pericytes per mm capillary length and (B) the number of EC per mm 
capillary length were quantified using automated image analysis in 15 randomly selected 
images per retina in iDTR; M-Cre (+tamoxifen, no DT, n=8), M-Cre (+tamoxifen, +DT, 
n=7), and iDTR; M-Cre (+tamoxifen, +DT, n=8) mice. There was approximately 7-15% 
pericyte loss in DT-treated iDTR; M-Cre mice compared to control. * P=0.0251 
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Figure 17. Retinal microvascular abnormalities in a model of inducible mural cell 
loss. 
The retinal vasculatures were digested from iDTR; M-Cre (top left panel), DT-treated M-
Cre (top right panel) and DT-induced iDTR; M-Cre (bottom panel) retinas and stained 
with periodic acid-Schiff (PAS) and hematoxylin. Acellular capillaries (bottom panel, 
arrows) were observed in elastase digests of retinal vessels from DT-treated iDTR; M 
Cre+ mice. Scale bars = 50 µm. 
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Figure 18. Quantification of acellular capillaries in an inducible model of mural cell 
loss. 
The number of acellular capillaries per capillary length was evaluated in elastase digests 
of retinal microvasculatures using quantitative image analysis automation in 10 randomly 
selected images per retina in iDTR; M-Cre (+tamoxifen, no DT, n=8), M-Cre 
(+tamoxifen, +DT, n=7), and iDTR; M-Cre (+tamoxifen, +DT, n=8) mice. 
Approximately twice as many acellular capillaries were observed in DT-treated iDTR; 
M-Cre mice versus controls. * P < 0.05  
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CHAPTER 3 
ESTABLISHING A LONG TERM MOUSE MODEL OF INDUCIBLE MURAL 
CELL DEATH 
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AIM 
To establish a long-term adult mouse model of inducible mural cell loss in the retina.  
 
RATIONALE 
The mouse model of inducible mural cell loss described above uses systemic 
administration (IP) of tamoxifen and DT and allows for acute examination of the effects 
of pericyte loss on the retinal microvasculature (see Chapter 2). A limitation of this 
approach is that the model of inducible mural cell loss does not allow for analyses of the 
chronic effects of pericyte loss in vascular stability. About one week after DT injection, 
animals show signs of distress most likely caused by systemic effects of DT on non-
vascular smooth muscle cells. Consistent with this interpretation, our mice did not show 
significant levels of mural cell loss from large vessels, as has been shown to occur in 
other mural cell death models (Clarke 2006). It would be of interest to analyze the long-
term effects of pericyte cell loss on vascular stability and to determine to what extent 
late-stage DR is observed. Therefore, I sought to develop a model that would allow us to 
investigate the long-term effects of pericyte loss in retinal vascular stability in non-
diabetic mice by locally inducing death of mural cells in adult mouse eyes.  
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RESULTS 
 
Local adminstration of DT: a low dose pilot study 
iDTR; M-Cre mice were established as described in Chapter 2. iDTR; M-Cre mice were 
injected IP with tamoxifen (500 ng in 225 µl corn oil) at adult age (eight-weeks old). To 
determine the dose of DT that would provide a gradual loss of mural cells, DT (0, 35 fg, 
or 350 fg in saline) was intravitreally injected six months after tamoxifen administration 
(eight-months old), as this was the age of the mice available for this pilot study (Figure 
19). The beginning dose of DT (35 fg) was determined by taking the dose (1 µg DT) used 
in the systemic model of mural cell loss (see Chapter 2) and adjusting for the difference 
between the total mouse body volume (estimated as 20 ml) and the intravitreal space (7 
µl). A higher (10X) dose of 350 fg DT was also included in this pilot series. Since Cre 
induction is permanent, there was no concern about the length of time between the 
administration of tamoxifen and DT. 
I sought to validate that local administration of DT the iDTR; M-Cre mice would lead to 
death of mural cells (SMCs and pericytes). Whole retinal flat mounts were stained for 
isolectin B4 (green) to detect ECs and TUNEL (red) to detect cell death. Five days after 
DT injection, there was staining of non-vascular cells by isolectin B4; these are likely 
macrophages and reflect inflammation from the intravitreal injection of DT (Figure 20). 
In addition to binding ECs, isolectin b4 binds to cell membrane glycoconjugates 
containing terminal alpha-D-galactose, which are present in macrophages (Sorokin and 
Hoyt 1992). Thus, five days post-intravitreal injection of DT was too early for analysis 
due to inflammation.  
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Next, I examined the retinal vasculature at one-month post-intravitreal DT injection. 
Whole retinal flat mounts were prepared and stained for alpha-smooth muscle actin (α-
actin, green) to detect mural cells and TUNEL (red) to detect cell death. Unlike the five-
day time point, there was no evidence of an inflammatory response. However, there was 
also no evidence of the loss of mural cell investment at either dose of DT (Figure 21). 
Thus, it appears that the doses of DT used were not sufficient to induce mural cell death 
and higher doses of DT are necessary.  
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Figure 19. Pilot study timeline using local administration of low dose DT in iDTR; 
M-Cre mice. 
iDTR; M-Cre mice were treated daily with tamoxifen (IP, 500 ng in 225 µl corn oil) for 
three days at eight-weeks of age. Six months after tamoxifen treatment, mice were 
intravitreally injected once with DT (0 fg, 35 fg, or 350 fg in saline). Five days and one 
month post-DT administration mice were euthanized and tissues were harvested for 
analysis. 
 
 
 
 
	   59	  
 
 
Figure 20. Intravitreal injection of DT causes inflammation in the retina at five days 
post-injection.  
Retinal flat mounts of iDTR; M-Cre mice intravitreally injected with saline (top left 
panel), 35 fg DT (top right panel), or 350 fg DT (bottom panel) were stained for isolectin 
B4 (green) to detect ECs and with TUNEL (red). Inflammation in the retina was evident 
five days after DT administration. Scale bar = 100 µm 
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Figure 21. Local administration of low dose DT does not cause mural cell loss in 
iDTR; M-Cre mice. 
Retinal flat mounts of iDTR; M-Cre mice intravitreally injected with saline (left panel), 
35 fg DT (middle panel), or 350 fg DT (right panel) were stained for smooth muscle actin 
(α-actin, green) to detect pericytes and with TUNEL (red). Loss of pericyte investment 
and microangiopathies were not observed. Scale bar = 100 µm. 
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Local adminstration of DT: a high dose pilot study 
Results of the pilot study indicated that 350 ng DT in the iDTR; M-Cre mouse eye is not 
sufficient to cause mural cell death. So a second pilot study was undertaken using higher 
levels of DT. Adult (eight-weeks old) iDTR; M-Cre mice were IP injected with 
tamoxifen (500 ng in 225 µl corn oil) daily for three days and three months later DT (0 
ng or 7 ng in saline) was intravitreally injected (Figure 22). This higher does was 
calculated using the dosage (1 µg DT) established in the systemic model of mural cell 
loss (see Chapter 2) and taking into account the total mouse blood volume estimated as 1 
ml (versus body volume used in the first calculation) and the intravitreal space (7 µl).   
Two weeks post-intravitreal injection, gross retinal vascular anatomy was examined 
using fundus photography. No overt changes in retinal vasculature were observed post-
tamoxifen treatment (IP) (Figure 23A), however hemorrhages were observed after 
intravitreal injection in the presences and absence of DT (black arrows, Figure 23B).  
Fluorescent angiography (FA) revealed mild leakage in the vehicle- and DT-treated 
iDTR; M-Cre mice (Figure 24). Interestingly, intravitreal injection of DT in iDTR; M-
Cre mice appears to be associated with decreased vessel width (Figure 24). In addition, 
fluorescein perfusion was delayed in DT-treated iDTR; M-Cre mice compared with 
vehicle-treated control (Figure 24). Also, vascular secondary branch perfusion was 
observed in vehicle-treated iDTR; M-Cre mice, but not in DT-treated iDTR; M-Cre mice 
(Figure 24).  
The hemorrhages observed in this high dose (7 ng DT) pilot study may be indicative of 
damage caused by intravitreal injection. An additional challenge in intravitreally injecting 
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adult mice is the possibility of puncturing the lens with the needle, which causes opacity 
and can lead to cataracts (data not shown). While the study presented here is a small pilot 
study (n=4 for each group), the data suggests that vascular changes may be occurring in 
the DT-treated iDTR; M-Cre mice. However, further analysis is required to determine the 
exact changes occurring after intravitreal injection of DT in iDTR; M-Cre mice and these 
studies are ongoing. Taken together, these data suggest that the intravitreal injection 
technique requires refinement and further development, but remains a viable option for 
establishing a long-term model of inducible mural cell loss.  
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Figure 22. Pilot study timeline using local administration of high dose DT in iDTR; 
M-Cre mice. 
iDTR; M-Cre mice were treated daily with tamoxifen (IP, 500 ng in 225 µl corn oil) for 
three days at eight-weeks of age. Three months after tamoxifen treatment, mice were 
intravitreally injected once with DT (0 ng or 7 ng in saline). Two weeks post-DT 
administration mice were analyzed for retinal vascular changes. 
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Figure 23. Live imaging in iDTR; M-Cre mice in high dose pilot study.  
Fundus photography of retinal vasculature in adult iDTR; M-Cre mice A) post-tamoxifen 
treatment (IP) and B) two weeks post-intravitreal injection of DT (0 ng or 7 ng in saline). 
Hemorrhages (black arrows) occurred after intravitreal injection in the presence and 
absence of DT in iDTR; M-Cre mice. Mouse retinal vasculatures imaged post-tamoxifen 
treatment in A (left) were assessed again following intravitreal injection of vehicle or DT 
in B (right).  
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Figure 24. Vascular permeability changes in retinal microvasculature of mice with 
local induction of mural cell loss. 
Vehicle-treated iDTR; M-Cre (first row) and DT-treated iDTR; M-Cre (second and third 
rows) mice were injected with 25% fluorescein sodium in saline (60 mg/kg mouse) prior 
to fundus photography. iDTR; M-Cre mice intravitreally treated with DT were observed 
to have thinner vessels (second and third rows) compared to vehicle-treated iDTR; M-Cre 
mice (first row). Intravitreally DT-treated iDTR; M-Cre mice had delayed fluorescein 
perfusion (second and third rows) compared to intravitreally injected vehicle controls 
(first row). Mouse retinal vasculatures evaluated in this experiment correspond with the 
same mouse eyes imaged in Figure 23.  
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CHAPTER 4 
DISCUSSION 
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DISCUSSION 
Developing a model of inducible mural cell loss  
To directly examine the role of the pericyte in the pathogenesis of DR, it is essential to 
have a model that allows the investigation of pericyte loss in the adult retinal vasculature 
without the added complexity of diabetes, hyperglycemia, obesity, and/or obstructing a 
major signaling pathway. To accomplish this, mice carrying a floxed allele of the iDTR 
(Buch 2005; Brockschnieder 2004) were bred with mice expressing tamoxifen-inducible 
Cre recombinase under the control of the M-Cre promoter (Wirth 2008). Mice with 
induced expression of DTR are DT-sensitive because they express a simian DTR, a 
heparin-binding epidermal growth factor-like growth factor (HB-EGF) precursor (Buch 
2005). In iDTR mice there is an upstream loxP-flanked STOP sequence that is deleted in 
the presence of Cre, thereby activating the expression of DTR (Buch 2005). In M-Cre 
(control) and iDTR; M-Cre (experimental) mice, the M-Cre promoter controls Cre 
recombinase that has a modified estrogen receptor-binding domain (CreERT2) (Indra 
1999; Wirth 2008). Cre-mediated recombination has been shown to occur exclusively in 
SMCs in SMMHC-CreERT2 (M-Cre) mice (Wirth 2008). Thus, upon M-Cre induction by 
tamoxifen, DTR expression is activated, rendering the mice DT sensitive. Subsequent 
administration of DT to these mice will lead to mural cell death. 
In 1884, it was first discovered that Corynebacteriym diphtheriae causes diphtheria 
(Loeffler 1884). In the 1920’s, the US had approximately 100,000-200,000 cases per year 
of diphtheria, of which 13,000-15,000 infected people died each year (Center for Disease 
Control 2012). Beginning in the 1930’s, the wide use of vaccinations (typically diphtheria 
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toxoid in combination with tetanus toxoid and pertussis vaccine) has virtually eradicated 
diphtheria from most developing countries (Center for Disease Control 2012). 
Corynebacteriym diphtheriae produces DT, a single polypeptide chain made of 535 
amino acids (~62 kDa) (Roux 1988; Pappenheimer 1977). DT is readily divided into two 
components (fragment A (DT-A) and fragment B (DT-B)) following separation of a 
single peptide and disulfide bond (Pappenheimer 1977). On the cell surface, DT-B binds 
to the DTR (HB-EGF precursor) and then internalized by the cell through receptor-
mediated endocytosis (Saito 2001). Following translocation into the cytoplasm, DT-A 
inactivates elongation factor 2 (EF2) through catalysis, which results in protein synthesis 
inhibition and subsequent apoptosis in the target cell (Saito 2001; Buch 2005). Since 
murine (mouse) HB-EGF precursors do not bind DT-B, they are not DT sensitive (Saito 
2001; Buch 2005). In the iDTR; M-Cre system employed for this study, mice express the 
simian (monkey) HB-EGF precursor (DTR), thus rendering them sensitive to DT (Buch 
2005).  
Whereas mouse models using the iDTR system with various Cre promoters have been 
demonstrated in the literature, none had employed the M-Cre promoter to induce mural 
cell death in mice. For example, using an oligodendrocyte-specific promoter (MOGi-Cre) 
with the iDTR system led to tremors, hind limb paralysis, and myelinated structure 
annihilation in the CNS, showing that DT can cross the BBB and access the CNS with 
systemic induction (IP) (Buch 2005). In addition, the iDTR system has been used to 
acutely ablate melanopsin-expressing retinal ganglion cells, which caused a deficiency in 
non-image forming visual functions, demonstrating that through systemic administration 
DT has access to the retinal space (Hatori 2008).  
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Therefore, to characterize iDTR; M-Cre mice, I had to first establish a timeline and 
dosage for induction of mural cell death. Numerous variables were examined including 
the use of active versus precursor tamoxifen, varied doses of tamoxifen and DT, and 
altering the time between DTR activation and administration of DT. In the final protocol 
that was used in the experiments presented in this thesis, adult (eight-weeks old) mice 
were IP injected on three consecutive days with tamoxifen to activate the DTR. Then, to 
induce mural cell death, DT was injected IP eight to ten weeks after tamoxifen 
administration. The effects of DT-induced mural cell death in adult mouse retinas (16-18-
weeks old) were examined with particular attention to spatial and temporal resolution 
(Figure 5). 
To ensure that the alterations that occur in the DT-treated iDTR; M-Cre do not influence 
major physiologic endpoints, blood glucose and plasma insulin levels were measured. 
Blood glucose measurements between the control and DT-treated iDTR; M-Cre mice did 
not vary with either treatment (tamoxifen or DT) (Figure 8A). Similarly, there was no 
significant difference in plasma insulin (collected post-mortem) levels among the groups 
(Figure 8B).  
 
Limitations of the model 
 
The iDTR; M-Cre mice began to show signs of deterioration eight days after the first DT 
injection. This decline in health is most likely the result of the fact that the promoter 
driving Cre would lead to the expression of iDTR in all smooth muscle (vascular and 
visceral) so that in addition to being expressed in by vascular SMCs, the iDTR would be 
expressed by nonvascular SMCs in organs such as the bladder and intestine. In support of 
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this, iDTR; M-Cre mice displayed reduced body and liver weight following 
administration of DT (Figure 9). To avoid the complications that these issues might 
cause, I focused my investigation on a time point five days after the first DT injection, 
when iDTR; M-Cre mice were healthy and active. 
Since DR develops over the course of decades, it would be worthwhile to determine to 
what extent late-stage DR, including components such a new vessel growth, is observed 
in mice with pericyte cell loss over time. In preliminary studies for creating a long-term 
model of mural cell loss, I administered DT (0, 35, 350 fg in saline) by intravitreal 
injection. In the initial pilot study, the dosage of DT was apparently too low as it did not 
cause mural cell death. However, a subsequent pilot study with intravitreal injection of a 
higher dose of DT (7 ng in saline), suggested that vascular changes may be occurring in 
iDTR; M-Cre (Figure 24). There are ongoing efforts to establish a long-term mouse 
model of mural cell death. 
The M-Cre promoter drives expression of iDTR in mural cells, including both SMCs and 
pericytes. However, total ablation of mural cells is not observed and this was likely due 
to the mosaic effect of the M-Cre promoter. While this could be seen as a limitation of 
the model, it also has advantages, because it better approximates the time course of 
pericyte loss in DR, where mural cells are not lost simultaneously but rather die over the 
course of many years.  
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Models of pericyte deficit 
 
Pericyte loss is an early pathological finding in DR and is temporally correlated with a 
number of other features of DR microangiopathy (Cogan 1967). PDGF-B and PDGFRβ 
null mice have been shown to have pericyte and/or SMC loss and develop 
microangiopathies associated with DR. However, as these models are generated by germ 
line deletions, they can only reveal the role of the mural cell in vascular development, 
rather than in pathology. Accordingly, approximately 25% of the PDGF-B mutants mice 
are embryonic lethal while a majority (~75%) die perinatally (Leveen 1994). Similarly, 
PDGFRβ -/- mice lack pericytes and SMC, are perinatal lethal, and display purpura, 
anemia, microaneurysms and thrombocytopenia (Soriano 1994). 
During vessel maturation, pericytes associate with ECs, leading to the deposition of BM 
and inhibition of migration and proliferation in both cell types (Orlidge and D’Amore 
1987; Sato and Rifkin 1989; Stratman 2009 and 2010). However, the role of pericytes in 
vascular stability in adult vessels has not been fully elucidated. Relevant mechanisms 
may include pericyte regulation of EC-gene expression including regulation of matrix 
metalloproteinases (MMPs). For example, changes in BBB-specific gene expression were 
reported in PDGF-B mutant adult mice (PdgfbRet/Ret and R26P+/0) with pericyte 
deficiency, indicating a role for vessel stability EC-gene expression regulation by 
pericytes (Armulik 2010). Pericyte-derived tissue inhibitor of metalloproteinases (TIMP) 
-3, a known regulator of vascular stability, has been shown to block MMP-1 and -10 
activity in EC-pericyte co-cultures (Saunders 2006). Thus, spatial and temporal 
regulation of EC-pericyte interactions is necessary for vascular stability.  
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Effects of diabetes on pericytes 
Pericyte loss has long been associated with DR (Kuwabara and Cogan 1963). The 
association of hyperglycemia with pericyte loss has been most closely studied in animal 
models (galactosemia), which have been characterized by initial loss of pericytes 
followed by subsequent vascular damage, including microangiopathies observed in DR 
(Kern and Engerman 1996; Mizutani 1996). In vitro studies have shown that high glucose 
leads to pericyte apoptosis (Kowluru 2010; Geraldes 2013). In addition, pericyte 
apoptosis is not protected when BRPs are cultured in high glucose and returned to normal 
glucose environment (Kowluru 2010; Geraldes 2013). However, the mechanism by 
which pericyte loss occurs in the retina has not fully been elucidated. 
A recent study implicates the protein kinase C (PKC) pathway in pericyte loss in high 
glucose environments. Pericyte loss is associated with PKCδ upregulation in 
hyperglycemic conditions in vitro, using BRPs cultured in high glucose, and in vivo, 
using STZ-induced diabetic mice (Geraldes 2013). Interestingly, diabetic PKCδ null mice 
(Prkcd-/-) do not develop pericyte loss or subsequent microangiopathies associated with 
DR such as acellular capillaries and retinal permeability (Geraldes 2013). Thus, PKCδ 
plays an important and specific role in pericyte loss under hyperglycemic conditions such 
as those found in DR. 
Increased levels of VEGF appear to play a role in permeability changes associated with 
DR, as anti-VEGF therapy has been shown to reduce macular edema and is currently 
approved by the FDA for its treatment (Massin 2010). Our laboratory has previously 
demonstrated the production of VEGF by a subset of retinal pericytes (Darland 2003).  It 
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is interesting to speculate that the observed increase in microvascular permeability in 
background DR may be due to glucose-induced increase in pericyte secretion of VEGF.   
 
Models of DR 
Some aspects of DR have been documented to develop in various mouse models of 
diabetes. Microaneurysms have been demonstrated in the retinas of mice fed high 
galactose for 21-months (galactosemia) (Kern 1996) and Akimba (Ins2Akita VEGF+/-) 
mice displayed retinal microaneurysms as early as eight-weeks of age (Rakoczy 2010). 
However, both the galactosemia and Akimba mice are hyperglycemic making it 
impossible to identify the cause of the retinal microaneurysms. Saccular microaneurysms 
were clearly identified in the retina five days after the administration of DT in the model 
of inducible mural cell death, indicating that pericyte loss leads to the development of 
microaneurysms (Figure 13). The association of pericytes with ECs inhibits EC migration 
and proliferation (Olridge and D’Amore 1987; Antonelli-Olridge 1987; Sato and Rifkin 
1989; Hirischi 1999). When pericytes are lost, as demonstrated in the model of inducible 
mural cell loss, ECs are no longer suppressed and are able to migrate and proliferate 
(Kuwarabara and Cogan 1963; Crocker 1970), leading to changes in BM composition 
and local dilation of the vessel, which forms microaneurysms.    
Loss of pericytes also precedes the appearance of acellular capillaries in human DR 
(Cogan 1961; Engerman 1987) as well as in many mouse models of diabetes (STZ, 
galactosemia, db/db, Ins2Akita) (Kern 1996; Barber 2005; Rakovcy 2010; Midena 1989; 
Schlingemann 1990; Ozerdem 2001). In iDTR; M-Cre mice treated with DT, long 
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stretches of capillaries lacking pericytes and ECs were observed, whereas acellular 
capillaries were rarely noted in control mice (Figures 17 & 18). This observation supports 
the concept that mural cell loss leads to the formation of acellular capillaries. Pericyte-EC 
interactions are tightly regulated. Previous work in the D’Amore lab has shown that 
pericyte-derived VEGF is necessary for EC survival (Darland 2003). Taken together, this 
evidence suggests that loss of pericytes leads to localized EC death. When pericytes, and 
subsequently ECs, are lost in a sequential manner along a capillary, acellular capillaries 
develop.    
Although macular edema is a common and vision-threatening complication of diabetes, 
its pathobiology remains unclear (Antonetti 2012). Ins2Akita mice displayed increased 
vascular permeability after 12-weeks of hyperglycemia (Barber 2005) and the Akimba 
(Ins2AkitaVEGF+/-) mice exhibited vascular leakage between eight and 16-weeks of age 
(Rakoczy 2010). I detected increased vascular permeability as evidenced by the leakage 
of fluorescein-dextran five days after DT treatment, indicating that pericyte loss leads to 
breakdown of the BRB (Figure 14). Loss of pericytes results in changes in EC phenotype, 
including loss of tight junction proteins, which results in EC migration and proliferation. 
In addition, pericyte loss can lead to EC death due to the lack of pericyte-derived VEGF 
(Darland 2003). Pericyte loss may also lead to changes in the BM composition, leading to 
increased permeability. These changes indicate that pericytes are necessary for 
maintaining the BRB.  
In addition, vessel tortuosity was observed in iDTR; M-Cre mice treated with DT and 
was not only temporally but spatially associated with the absence of mural cells 
(Supplemental Figure 2, arrowheads). The Akimba mouse is the only diabetic mouse 
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model for which retinal vessel tortuosity has been reported (Rakoczy 2010). While my 
results indicate that vessel tortuosity is due to mural cell loss, how the absence of 
pericytes leads to this phenotype is not obvious.  The tortuosity may result from 
stretching and releasing motion of the vessels or a collapsing of the vessel. It may also be 
due to increased EC proliferation that would be expected to occur with pericyte loss.  
This model of inducible mural cell loss should be a helpful tool in elucidating the 
mechanism of this vessel abnormality.  
The inducible model of mural cell loss that I have established displays a number of 
features that are characteristic of early stage or non-proliferative DR. Despite the severity 
of the phenotype (Figures 10-14), the burden of pericyte loss underlying microangiopathy 
in this model was relatively low (7-15%, Figure 16A).   
 
Algorithm development and importance 
Retinal pericyte and EC have been quantified in human retinal vasculature, as well as in 
several animal models using trypsin digests (Speiser 1968; Laver 1993; Kern and 
Engerman 1996; Hammes 1997; Zhang 2012). However, due to the difficulty of 
distinguishing between these two cell types in mice, retinal pericyte and EC counts have 
not been achieved in mouse models of DR. Since the model presented here depends on 
genetic manipulation, it was imperative that I develop a means to reliably quantify the 
individual vascular cells in the mouse retina. Therefore, working with Wimasis Imaging 
Analysis, I established an automated technique to quantify pericytes and ECs in elastase 
digests of mouse retinal vasculature (see Chapter 6).   
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Pericyte and EC were identified by size and morphology using an algorithm that employs 
aspect ratios and eccentricities. It has been shown that EC align in the direction of blood 
flow (Tkachenko 2013) and this feature leads to elongated nuclei so that ECs have a 
larger aspect ratio. On the other hand, pericytes are more round in shape than ECs, 
allowing eccentricity to be used to distinguish pericytes from ECs. Additional criteria 
were also incorporated to prevent false positives. For example, nuclei were excluded 
from the analysis if they were partially cut from view, overlapping with other nuclei, or 
on a vessel larger than a capillary (Figure 25).  
Using these criteria, I created an automated methodology for quantifying pericytes and 
ECs in digests of the mouse retinal microvasculature. The algorithm, 
Wim_EC_Perycite_Count_Beta_1.02, is now available through Wimasis Imaging 
Analysis for other scientists to use in their analysis of mouse retinal microvasculature. In 
this regard it would be of interest to the field to know the pericyte:EC ratios in other 
models of that display pericyte loss such as PDGF-B and PDGFRβ null mice as well as 
diabetic mice, including as STZ-induced diabetes, db/db mice, and galactosemic mice. 
In the discussion of DR, there is no specific definition of what constitutes an acellular 
capillary. Yet, in order to quantify acellular capillaries as an endpoint it is necessary to 
have specific criteria. I therefore partnered with Wimasis Imaging Analysis to develop an 
automated technique for classifying capillaries as acellular (see Chapter 6). We decided it 
was important to identify a minimum length of capillary that was cell free, but we needed 
to first ascertain the mean internuclei distance along the retinal capillaries in wild type 
mice. In the first iteration of the algorithm capillaries were considered to be acellular if 
they lacked nuclei along a length greater than two standard deviations above the mean 
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internuclei distance. However, when this algorithm was tested, it was found to created a 
high number of false positives. I therefore conducted manual analysis and then iteratively 
used that data to create a model that accurately recognizes acellular capillaries. 
Additional parameters including a minimum width of one-fourth of a normal capillary 
and excluding vessels larger than capillaries were also applied to avoid false positives. 
The resulting algorithm, Wim_Acellular_Capillaries_Beta_1.03, is accessible for other 
labs to use in their analysis of acellular capillaries in mice.  Again, this tool should be 
useful to quantify changes in other reported models of background DR, which to date 
have largely been reported in a qualitative fashion.  
 
 Current treatments of DR 
The only way to prevent or delay the development of DR is hyperglycemic control. It is 
extremely challenging for diabetics to maintain normal glycemic ranges and often 
requires the use of many drug combinations, insulin injections, and/or a strict diet. When 
faced with the task of maintaining normoglycemia, diabetic patients often straddle the 
line between normal and either hyper- or hypo-glycemic blood glucose levels. In a six-
year study, the Diabetes Control and Complications Trial Research Group tested the 
effects of intensive glucose control (three or more daily insulin injections with dosage 
based on blood glucose measurements made at least four times per day) versus 
conventional therapy (one or two daily insulin injections with self-monitoring of blood 
glucose daily) on DR progression in type I diabetics (The Diabetes Control and 
Complications Trial Research Group 1993). In patients with no signs of retinopathy at the 
start of the study, there was a 76% reduced risk of DR development in the intensive blood 
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glucose control cohort (The Diabetes Control and Complications Trial Research Group 
1993). In addition, patients with early DR in the intensive blood glucose control cohort 
had a 54% decreased risk of further DR development (The Diabetes Control and 
Complications Trial Research Group 1993).  
Current therapies for PDR include pan-retinal photocoagulation (PRP), surgical removal 
of the vascular outgrowths, and more recently, anti-VEGF therapy (Jardeleza 2009; 
Newman 2010; Tonello 2008). PRP, the current gold standard for the treatment of PDR, 
involves the placement of laser burns throughout the retina. This treatment has been 
shown to reproducibly lead to the regression of new vessels, thereby reducing the risk of 
central vision loss (Tonello 2008). Interestingly, the mechanism whereby PRP controls 
the neovascularization is not understood.  There is speculation that by destroying highly 
metabolic neural retinal tissue the need for oxygen is reduced, thus reducing the 
expression of hypoxia-induced VEGF.  It has also been suggested that the laser injury 
thins the retina, allowing more diffusion from the underlying choriocapillaris.  However, 
in the process of saving the patient’s central vision, PRP often causes loss of peripheral 
vision (Tonello 2008). Since anti-VEGF therapy is the only FDA-approved treatment of 
macular edema, which may appear at any stage of the disease, it is rarely used off-label in 
PDR as a surgical adjuvant because it has been shown to trigger retinal detachment 
(Massin 2010; Sohn 2012).  
Nearly all of the current treatments of DR are focused on the late-stage of DR, PDR, 
when the disease has already progressed and may already be vision-threatening. Despite 
some progress in the treatment of DR, the understanding of the molecular and cellular 
mechanisms underlying the development of DR remains incomplete. Thus, it is essential 
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that new therapeutics be developed to treat early stage or non-proliferative DR before the 
disease has advanced to vision loss.  
 
Therapeutic potential 
To identify more effective therapies, and perhaps more importantly preventative 
interventions, it is essential to identify molecular and cellular targets that initiate the 
cascade of events leading to DR. This model has allowed me to directly examine the role 
of pericyte loss in the development of diabetic microangiopathy and highlights the role of 
pericytes in instigating DR pathology in the retinal microvasculature. My results indicate 
that pericyte protection, rescue, or replacement may be a viable therapeutic target.  
The mouse model of inducible mural cell loss could be used to pursue therapeutic 
treatment to rescue pericyte coverage in the adult. For example, intravitreal injection of 
pericyte recruiting proteins such as PDGF-B in the inducible model of mural cell loss 
may lead to restoration of pericytes. In a similar vein, new therapeutics that aim to recruit 
pericytes in patients with early DR could be tested in the inducible model of mural cell 
loss either acutely or long term to determine if they have pericyte restoring capabilities. 
Because the model of inducible mural cell loss can have dramatic effects acutely, this 
model could save a considerable amount of time in drug discovery compared to other 
models of DR, which require several months to a year to develop microangiopathies.  
In addition, the inducible model of mural cell loss could be used to examine the viability 
of cell replacement therapy. For example, it has been demonstrated that intravitreal 
injection of healthy human endothelial progenitor cells (CD34+ EPCs) are able to 
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incorporate into the vasculature of diabetic mice (Caballaro 2007). Further, EPCs have 
been used in a number of clinical trials and have promising results in ischemic patients 
who display with improved perfusion following EPC administration (Tongers 2010). In 
addition, MSCs have been used as a multi-faceted approach to cell replacement therapy 
in diabetes aiming to improve cardiomyopathy, nephropathy, polyneuryopathy, and 
wound healing (Volarevic 2011). Thus, MSCs or progenitor cells differentiated into 
pericytes may provide a worthwhile mechanism for approaching cell replacement as a 
potential therapeutic in DR. 
 
Future Directions 
Limited by the effects of systemic mural cell loss, the version of the mouse model of 
inducible (IP) mural cell loss reported here allows for acute examination of the effects of 
pericyte loss on the retinal microvasculature (see Chapter 2). To determine the 
consequences of pericyte loss on vascular stability over time and to what extent late-stage 
DR might be observed, it would be interesting to analyze a long-term model of pericyte 
cell loss. In the work presented in this thesis, I completed an initial study to develop a 
longer-term model of mural cell loss. In these preliminary studies iDTR; M-Cre mice 
locally treated with DT were not observed to have mural cell loss.  
I suspect that higher doses of DT than those used in the pilot study will be necessary to 
induce mural cell death via local administration. Although it is certainly possible that the 
DT administered intravitreally is not accessible to the pericytes, the fact that the pericytes 
are on the outside of the retinal capillaries and not shielded by the BRB reduce this 
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possibility. Further, the success of intravitreal anti-VEGF therapies (ranging from 48-149 
kDa), which is also presumably outside of the vasculature makes this less likely (Keane 
2012).  
If after reasonable efforts we find that intravitreal DT administration is not effective, 
another option would be to drive Cre expression with a promoter that is not expressed by 
nonvascular (visceral) muscle cell. Mice expressing Cre under the control of smooth 
muscle protein 22-alpha (SM22α) promoter, which is specific for vascular SMCs, could 
be crossed with the iDTR mice to create a model that can be systemically induced and 
would allow for long-term studies of mural cell death. It has been shown that systemic 
induction in iDTR; SM22α-Cre mice causes a 50-70% loss of vascular SMCs (Clarke 
2006), but does not lead to lethality. Importantly, it has been reported that iDTR; SM22α-
Cre mice maintain normal cellularity in their small intestine and bladder SMCs (Clarke 
2006).  
This model of inducible mural cell loss would allow examination of long-term effects of 
pericyte loss including effect on EC gene expression. Although gene expression studies 
could also be conducted in the model of acute pericyte loss that I have characterized in 
this thesis, the relatively low level of pericyte loss may lead to reduced signal (e.g. only a 
small percentage of the vasculature is effected).  In contrast, loss of more pericytes in a 
longer-term model might be expected to affect more of the vasculature and make such 
array analysis more likely to succeed.   
In addition, aorta-derived SMCs from untreated iDTR; M-Cre mice cocultured with ECs 
would provide an inducible in vitro system to study the consequence of pericyte loss on 
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EC gene expression patterns. In DR, there is EC dysfunction in response to 
hyperglycemic condition, which coincides with pericyte loss. Since the model of 
inducible mural cell loss is not hyperglycemic, it could be used to investigate the role of 
pericyte loss in EC dysfunction. Based on the tightly regulated cell-cell interactions 
between pericytes and ECs, I predict changes in genes regulating EC proliferation and 
migration as well as metabolic and barrier functions. Further, the capillary BM 
dramatically thickens in diabetes, potentially creating a barrier between pericytes and 
ECs. Some signaling pathways such as Notch, which requires direct cell-cell contact 
between pericytes and ECs, will be compromised. The model of inducible mural cell loss 
could be a valuable tool to dissect the various signaling pathways involved in normal EC-
pericyte interactions.   
Similarly, gene expression patterns could be examined in surrounding cells that are 
involved in vascular function, such as Müller cells and astrocytes, to determine the 
impact of pericyte loss on these cell types. Whereas it has been well established that 
astrocyte-EC interactions are important for BBB function (Goldstein 1988; Abbott 2006), 
it is unclear if there are similarly important interactions between glial cells and pericytes. 
Thus, the model of inducible mural cell loss could reveal whether a role exists for glial 
cell-pericyte interactions in BRB maintenance and vascular integrity.  
The model of inducible mural cell loss develops hallmark characteristics of DR including 
microaneurysms and acellular capillaries, which are similar to the phenotypes (pericyte 
loss and acellular capillaries) observed in the STZ-induced diabetic model. Glial cells 
have been shown to be involved in DR. For example, following STZ-induction of 
diabetes, astrocyte gap junction proteins (connexin-26 and -43) are reduced in the adult 
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retina resulting in significant astrocyte loss (Ly 2011). STZ-induced diabetes also leads to 
Müller cell activation in the adult retina (Ly 2011). While currently there are no data 
suggesting a link between pericyte loss and the changes in glial cell found in DR, using 
the model of inducible mural cell loss may give insight into these interactions.   
While my studies have investigated the direct role of pericytes in microvascular stability 
in the absence of a diabetic milieu, there is potential to cross the iDTR; M-Cre mice with 
a diabetic mouse such as Akita or Akimba to determine if a more severe phenotype 
develops. Since the Akita and Akimba mice do not exhibit pericyte dropout, the loss of 
pericytes on a hyperglycemic background might be expected to lead to more dramatic 
phenotype, perhaps even mimicking late stage or proliferative DR. Alternatively, iDTR; 
M-Cre mice could be fed a high galactose diet with the aim of creating a more intense 
phenotype over a longer time course. While galactosemic mice do develop pericyte loss, 
this phenotype is only observed after a long time frame (many months).  
In addition to providing a model for investigating the pathogenesis of DR, the inducible 
mural cell loss model may be useful as a tool to study other small vessel diseases marked 
by pericyte loss such as CADASIL (cerebral autosomal-dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy), Alzheimer’s disease (AD), and multiple 
sclerosis (MS). Associated with NOTCH3 mutations, CADASIL is a neurodegenerative 
disease characterized by ischemic stroke and loss of vascular SMCs and pericytes 
(Arboleda-Velasques 2008; Dziewulska 2012). A neurological disorder, AD is associated 
with amyloid  β-peptide accumulation, tau pathology, BBB breakdown, neuronal loss and 
more recently, pericyte loss. Although the role of pericyte loss in AD is unclear, it is 
thought to be associated with the breakdown of the BBB (Zlokovic 2008). MS, an 
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autoimmune disease affecting the CNS, has a range of symptoms including visual 
disturbances, coordination and balance issues, and permanent neurological complications 
(Zlokoviac 2008). In MS, ECs and pericytes express vascular cell adhesion molecule-1 
(VCAM-1) and display T-cell adherence, suggesting a role for both cell types in the 
disease progression (Verbeek 1995). Since the role of pericyte loss in CADASIL, AD, 
and MS is unclear, the mural cell dropout model may serve as a unique and powerful tool 
to study their role in these pathologies. 
 
Concluding remarks 
Whereas pericyte-EC ratios in the retinal microvasculature of humans and animal models 
have been well studied, it has not been possible to conduct such analysis in mice due to 
the challenging nature of distinguishing the two cell types. In this work, I implemented a 
new technique to automate analysis of pericyte and EC quantification in mice. In 
addition, the criteria for classifying acellular capillaries have been ambiguous. Through 
the work in this thesis, I created a method to standardize acellular capillary 
quantification. Taken together, this work opens the door to continued understanding of 
the mechanism initiating the cascade of events leading to DR and a potential therapeutic 
for treating DR. 
Since the early 1960’s, when Cogan, Toussaint, and Kuwabara observed that 
microaneurysms formed in diabetic patients were associated with pericyte loss 
(Kuwabara and Cogan 1963), it has been widely accepted that pericyte loss precedes 
microangiopathies and generally assumed that loss of pericytes trigger these events. 
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However, it has not been possible to demonstrate a direct causal role for pericyte loss in 
these pathologies. Using the mouse model of inducible mural cell loss, I characterized 
retinal vascular changes in the adult caused by pericyte loss including microaneurysms, 
acellular capillaries, and leakage. The work presented here demonstrates the direct role of 
pericytes in vascular stability and provides critical evidence to suggest pericytes as a 
potential therapeutic target.  
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CHAPTER 5 
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
Mice  
iDTR; M-Cre (experimental) and M-Cre (control) mice were generated by breeding Cre-
inducible diphtheria toxin receptor (iDTR) transgenic mice (Buch 2005) with mice 
expressing tamoxifen-inducible Cre under the control of the smooth muscle myosin 
heavy chain promoter (SMMHC, M-Cre) (Indra 1999; Wirth 2008) (Stock numbers: 
007900, 019079, Jackson Laboratory, Bar Harbor, ME). Both experimental and control 
mice (8-weeks old) were injected intraperitoneally (IP) daily for three days with 
tamoxifen (500 ng in 225 µl corn oil, Sigma-Aldrich, St. Louis, MO). Eight to 10 weeks 
after tamoxifen administration, mice were injected IP with diphtheria toxin (DT; 500 ng 
in 100 µl saline, Sigma-Aldrich) daily for two days. The corn oil used to dissolve 
tamoxifen was completely absorbed and did not interfere with the bioavailability of DT. 
As a negative control, some iDTR; M-Cre mice did not receive DT. Mice were 
euthanized for analysis five days after the first DT injection. Littermates were used for 
comparative analysis throughout. All animal protocols were approved by the Schepens 
Eye Research Institutional Animal Care and Use Committee.  
 
Isolation and tamoxifen treatment of aorta-derived smooth muscle cells (SMCs)  
Aorta-derived SMCs were collected as previously described (Rong 2003). Briefly, aortas 
collected from iDTR; M-Cre mice were digested for 10 minutes at 37°C using 
collagenase II (175 units/ml, Worthington Biochemical, Lakewood, NJ) and dissected to 
remove the tunica adventitia layer. The length of the aorta was cut and ECs were 
manually removed using a polyvinyl acetal surgical eye spear (Braintree Scientific Inc., 
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Braintree, MA). The intact aorta tunica media layer was then cultured overnight in 10% 
FBS in Dulbecco’s minimal essential medium (DMEM). The following day, a mixture of 
collagenase II (175 units/ml, Worthington Biochemical) and elastase type I (0.5 mg/ml, 
Sigma-Aldrich) was added and incubated at 37°C for 1 hour and 15 minutes to create a 
single cell suspension of aorta-derived SMCs. Aorta-derived SMCs were grown in 20% 
FBS DMEM for 48 hr and then maintained in 10%FBS DMEM. Cultured iDTR; M-Cre 
aorta-derived SMCs were treated with vehicle (ethanol) or tamoxifen (1 µM in ethanol) 
for 48 hours in 10% FBS DMEM. 
 
RNA isolation and reverse transcription-PCR  
Total RNA was isolated from mouse tissues using phenol-chloroform extraction (TRIzol, 
Life Technologies, Grand Island, NY) and from aorta-derived SMCs using an RNeasy kit 
(Qiagen, Valencia, CA). Reverse transcription was performed using iSCRIPT (BioRad, 
Hercules, CA). The primers used included: 
Mouse Hprt1: 
F- TCAGTCAACGGGGGACATAAA; R- GGGGCTGTACTGCTTAACCAG 
Simian HB-EGF (DTR):  
F- GCAGATCTGGACCTTTTGAGA; R- CCCGGAGCTCCTTCACATATT 
qPCR was performed on a LightCycler 480II (Roche Diagnostics, Indianapolis, IN) using 
SYBR Green PCR Master Mix (Life Technologies). To calculate the fold-change using 
the standard 2-∆∆Ct formula, a Ct value of 35, corresponding to the lowest limit for 
detection, was used when signal was not detected for simian HB-EGF.  
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Biochemical measurements 
Blood was drawn from mice by submandibular bleeding using a sterile splinter out 
(MEDIpoint, Mineola, NY) prior to treatment (eight weeks old), post-tamoxifen 
treatment (16 weeks old), and post-DT treatment (16 weeks plus five days old). Blood 
glucose was measured using an ACCU-CHEK Compact Plus Glucometer (Roche 
Diagnostics). Blood plasma was collected post-mortem from M-Cre (+DT), iDTR; M-
Cre (-DT), and iDTR; M-Cre (+DT) mice and plasma insulin was measured by ELISA 
(ALPCO Diagnostics, Salem, NH). 
 
Immunostaining 
Flat-mounted retinas were permeabilized by incubation for 12 hr in PBlec (PBS minus 
salts, 0.1 mM CaCl2, 0.1 mM MgCl2, 0.1 mM MnCl2) with 0.1% sodium citrate, 0.1% 
BSA, and 1% Triton-100X. Following permeabilization, retinas were washed with PBS 
and incubated overnight at 4°C with either Griffonia simplicifolia isolectin-B4 conjugated 
to Alexa Fluor 488 (1:100, I21411, Life Technologies) to detect ECs, or with mAb anti-
smooth muscle actin conjugated to FITC (1:100, F3777, Sigma-Aldrich) to detect 
pericytes and SMCs. The retinas were visualized using an Axioskop 2 Mot Plus 
microscope (Zeiss, used for imaging throughout unless noted). These images were used 
to assess the presence of microvascular abnormalities including microaneurysms. 
 
TUNEL assay  
Following overnight immunostaining as described above, retinas were washed with PBS, 
fixed for 10 minutes at room temperature with 4% paraformaldehyde, and washed again 
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with PBS. TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) was 
carried out using the In Situ Cell Death Detection TMR red kit (1215672910, Roche 
Diagnostics), following the manufacturer’s guidelines. As positive and negative controls 
for each experiment, retinas from C57BL/6 mice were treated with DNase prior to 
TUNEL staining or were stained with only the TUNEL label solution without the 
terminal transferase, respectively. The retinas were then flat-mounted and TUNEL 
positive cells were visualized using fluorescence microscopy. The number of TUNEL 
positive cells per mouse retina was quantified in images that included every visible vessel 
in the retina.  
 
Elastase digests  
Eyes were fixed in 10% formalin for three days at 4ºC. Retinas were dissected from eyes 
and incubated in 0.15 M glycine in PBS overnight at 4ºC to remove excess formalin. The 
retinal vasculatures were then isolated using elastase digestion as described (Laver 1993; 
Zhang 2012). Briefly, retinas were incubated in elastase (324682, EMD Millipore, 
Billerica, MA) (40 unit/ml elastase in 100 mM sodium phosphate buffer, pH 6.5, 
containing 150 mM sodium chloride and 5 mM EDTA) for 1.5-2 hours at 37ºC.  Retinas 
were placed in a petri dish filled with sterile filtered autoclaved H2O and the vessels were 
cleaned by gently removing the neural retina using rat whisker brushes. Next, isolated 
vessels were mounted to a Superfrost Plus microscope slide (12-550-15, Fisher Scientific, 
Pittsburg, PA), dried overnight at room temperature, then stained with periodic acid-
Schiff (PAS; Sigma-Aldrich) and counterstained with hematoxylin (Sigma-Aldrich). 
Elastase digests were imaged by light microscopy.  
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Morphometry  
Isolated retinal networks were analyzed to determine the number of pericytes, ECs, and 
acellular capillaries. The total number of pericytes and ECs in 15 images and acellular 
capillaries in 10 images were quantified (magnification 700x). Fields examined were 
selected randomly (Supplemental Figure 4), excluding areas near the optic nerve and near 
the external border, and were analyzed using quantitative image analysis automation 
(Wimasis Imaging Analysis, Germany; described in detail in Chapter 6). ECs and 
pericytes were classified based on size and morphology using previously described 
morphological characteristics (Kuwabara and Cogan 1960; Cogan 1963; Speiser 1968). 
Acellular capillaries were defined as being a minimum of one-fourth the width of a 
normal capillary (Kern and Engerman 1993; Barber 2005) and displaying a nucleus-free 
length that was greater than the average internuclei distance calculated as 4(average + 
2*standard deviation). 
 
Fluorescein dextran perfusion  
Mice were perfused with fluorescein dextran as previously described (Saint-Geinez 
2008). Briefly, mice were deeply anesthetized using a mixture of ketamine (120 mg/kg 
IP) and xylazine (20 mg/kg IP) and perfused with 50 mg/ml fluorescein dextran (2x106 
mw, FD2000S, Sigma-Aldrich) in 4% paraformaldehyde in PBS. Eyes were then 
collected and fixed overnight in 4% paraformaldehyde at 4ºC prior to whole mount 
preparation. Fluorescein dextran perfused whole retinal flat mounts were visualized using 
a Nikon Eclipse E800 (Nikon Corporation, Brighton, MI). 
 
	   92	  
Intravitreal DT injections 
Mice were anesthetized with a ketamine (120 mg/kg) and xylazine (20 mg/kg) mixture. 
One drop of 1% tropicamide (Bausch + Lomb, Rochester, NY) followed by one drop of 
1% cyclopentolate hydrochloride (Altair Pharmaceuticals Inc., Aquebogue, NY) was 
applied to the cornea to dilate the pupils. GenTeal (Alcon Research Ltd., Sinking Spring, 
PA), an ocular lubricant, was applied as needed to keep eyes moist. Using a 
microsurgical microscope, a small incision was made behind the sclera near the cornea at 
the upper nasal limbus using the tip of a sharp 30-gauge needle. DT (0 fg, 35 fg, 350 fg, 
or 7 ng in saline) was injected into the vitreous using a 5 µl microinjection syringe with a 
32G blunt end removable needle (87931, Hamilton Company, Reno, NV). Following 
intravitreal injection, eyes were treated with a triple antibiotic (Neo/Poly/Bac) Puralube 
ointment (Fera Pharmaceuticals, Locust Valley, NY). 
 
Fundus photography 
Mice were anesthetized with a mixture of ketamine (120 mg/kg) and xylazine (20 
mg/kg). Pupils were dilated using one drop of 1% tropicamide (Bausch + Lomb) 
followed by one drop of 1% cyclopentolate hydrochloride (Altair Pharmaceuticals Inc.) 
applied to the cornea. Eyes were kept moist by applying the ocular lubricant Genteal 
(Alcon Research Ltd.) as needed. Both eyes were imaged using fundus photography 
(Micron III, Phoenix Research Labs, Pleasanton, CA). 
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Fluorescein angiography 
Prior to fluorescein angiography (FA), mice were imaged using fundus photography as 
described above. Mice were then IP injected with 25% fluorescein sodium in saline (60 
mg/kg mouse, NDC 46387-101-02, Alliance Inj LLC, El Paso, TX). Photographs using 
the Micron III (Phoenix Research Labs) were taken in the right eye of each mouse at 
regular time intervals (from 1 minute to 4 minutes post-IP injection). 
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CHAPTER 6 
MATERIALS AND METHODS: DEVELOPING AUTOMATED IMAGE 
ANALYSIS TECHNIQUES 
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MATERIALS AND METHODS 
Introduction 
In 1960, Kuwabara and Cogan first described a technique, called trypsin digest, for 
isolating the retinal vasculature (Kuwabara and Cogan 1960). According to Kuwabara 
and Cogan, the ECs were described as, “…large, ellipsoid nuclei lying within the wall 
and oriented along the axis of the capillaries and small vessels, but oriented 
circumferentially in the arteries and veins” (Kuwabara and Cogan 1960). The pericytes 
were defined as, “…smaller, darker, and usually round nuclei situated on the outer 
portions of the wall” (Kuwabara and Cogan 1960). Later, it was noted that pericytes often 
protrude from the vessel wall (Cogan 1963). Since their discovery, trypsin digests have 
been instrumental in understanding morphological differences in retinal microvasculature 
between normal and pathologic situations.  
Through the use of trypsin digests, it has been possible to quantify the presence of ECs, 
pericytes, ghost pericytes, microaneurysms, and acellular capillaries. Subsequently, an 
investigation by Speiser in 1968 demonstrated a dramatic change in the ratio of ECs to 
pericytes in the retina of normal (1:1) versus diabetic (4:1) patients (Speiser 1968). 
Similarly, trypsin digests have been studied to demonstrate the similarities between 
animal models and human disease. For example, an alteration in EC/pericyte ratio was 
observed in the retina of dog models (diabetic dogs (10:1) and galactosemia dogs (6.4:1)) 
compared to normal dogs (3.5:1) (Speiser 1968; Laver 1993; Kern and Engerman 1996; 
Hammes 1997; Zhang 2012). Thus, quantitative analyses of trypsin digests allow 
comparison among normal and diseased groups. 
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In 1993, Laver et al found that trypsin was not the active ingredient that digests away the 
neural retina (Laver 1993). Instead, their study exposed that elastase, a contaminant 
found in trypsin (215240, Difco, BD, Franklin Lakes, NJ), is the actual cause of digestion 
of the retinal neural tissue (Laver 1993). The use of elastase, rather than trypsin, has only 
recently begun to be introduced in the literature (Zhang 2012). Of note, the studies in this 
work were performed using elastase digests.   
 
Automated image analysis for pericyte and EC quantification 
Rationale 
Quantification of pericytes and ECs using trypsin digests of retinal microvasculature has 
been well established in humans, dogs, and rats, but not for mice (Speiser 1968; Laver 
1993; Kern and Engerman 1996; Hammes 1997; Zhang 2012). In a mouse model of DR, 
Tim Kern, a respected authority in animal models of diabetic retinopathy, stated, 
“Endothelial cell nuclei and pericyte nuclei were counted differentially in the midretina 
until approximately 1200 capillary cells per retina were counted; however, differentiation 
between these cell types was difficult, making the endothelial-pericyte ratio unreliable” 
(Kern and Engerman 1993). I therefore sought to establish an automated technique to 
quantify pericytes and ECs in mice.    
 
Algorithm Development 
Identification of pericytes and ECs in the automated system was based on size and 
morphology. Pericytes were defined as having nuclei round in shape most often found at 
vessel bifurcations or protruding from the vessels (blue, Figure 26B). ECs were defined 
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as having elongated oval-shaped nuclei (green, Figure 26B). The roundness of the object 
or eccentricity was set between zero and one, where zero is a circle and one is a straight 
line. Eccentricity was used to differentiate ECs from pericytes since the latter are 
rounder. In the first version of the algorithm, 0.745 was used as a threshold, but this was 
raised to 0.860 in the final version of the algorithm. Further, the ratio between the 
maximum and minimum length of the object called an aspect ratio, was used in 
combination with eccentricity to distinguish pericytes from ECs. ECs have a bigger 
aspect ratio because they have elongated nuclei. The aspect ratio was initially set to 2.45, 
but early analyses revealed that this ratio was too high and incorrectly classified many 
ECs as pericytes. Thus, the aspect ratio was lowered to 1.97 to more effectively classify 
the two cell types. In the initial version, the algorithm underestimated the number of ECs 
(78%), but overestimated the number of pericytes (190%) based upon my manual 
analysis. The final version of the algorithm showed significant improvement indicated by 
detection of 116% of ECs and 93% of pericytes compared to my manual analysis. Given 
that manual analysis is biased and varied by individual, the degree of concordance 
between the final version of the algorithm and my manual analysis appeared satisfactory. 
The algorithm will consistently detect ECs and pericytes within the parameters set above 
without variation, while manual analysis will always fluctuate, especially among 
individuals. All the parameters discussed here were set using a classifier designed by 
Wimasis Imaging Analysis, which is proprietary and therefore not included. 
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Figure 26. Automated image analysis for pericyte and EC counts.  
Retinal microvasculatures were isolated by elastase digestion and stained with periodic 
acid-Schiff (PAS) and hematoxylin. Pericyte (P, circles) and EC (rectangles) 
quantification by A) manual analysis and B) automated image analysis.  
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Nuclei on the periphery of the image (cut off from view) were excluded, as it is not 
possible to determine the cell type without viewing the entire nuclei. Also excluded were 
nuclei that were overlapping, as it was not feasible to reliably distinguish the morphology 
of each individual nuclei (red, Figure 27B). As a threshold between singular nuclei and 
overlapping nuclei, the maximum area was set to 3100 px. Additionally, the solidity, 
which is the surface area of the nuclei divided by the convex hull, was set to a minimum 
of 85% to discard overlapping nuclei. Further, to avoid false positives, the minimum area 
was set to 1000 px, which prevented debris from being detected as a nucleus. 
Since the analysis is focused on the retinal microvasculature, only capillary nuclei were 
quantified. By selectively quantifying capillaries, quantification was restricted to 
pericytes and SMCs were excluded from the analysis, such as nuclei of cells in large 
vessels (yellow, Figure 27B). Large vessels were defined according to a minimum length 
(750 px) and a minimum width (100 px). Nuclei with more than 50% of their surface on a 
large vessel were not included in the analysis. Since there are multiple vessel crossings 
and determination of their origin is challenging, an algorithm of minimum angle variation 
was applied to assign each branch to its precursor vessel.  Capillary length (in mm) was 
also required to standardize pericyte and EC counts among the groups.  
The final algorithm for automated image analysis of pericyte and EC quantification in 
mouse elastase digests (discussed above) was developed in collaboration with Wimasis 
Imaging Analysis and can be identified as, “Wim_EC_Perycite_Count_Beta_1.02.”  
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Figure 27. Automated image analysis parameters for pericyte and EC counts.  
Retinal vessels digested by elastase and stained with periodic acid-Schiff (PAS) and 
hematoxylin. A) Manual analysis showing exclusion factors for developing an algorithm 
to quantify pericytes and ECs. B) Automated image analysis of same image showing 
nuclei excluded in large vessels (yellow), in overlapping areas (red), or cut off from view.  
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Automated image analysis for quantification of acellular capillaries 
Rationale 
In a study of a DR mouse model, Tim Kern defined acellular capillaries as, “…basement 
membrane tubes lacking cell nuclei and maintaining at least one-fourth the normal 
capillary caliber over their length” (Kern and Engerman 1993). Because this definition 
does not specify a minimum length of vessel lacking nuclei, there currently is no 
standard. Therefore, I established an automated technique to quantify acellular capillaries 
in mice.   
 
Algorithm Development 
The specifications included in the initial algorithm framework to quantify acellular 
capillaries were that acellular capillaries do not have nuclei and must be a minimum of 
one-fourth the width of a normal capillary. Analysis using these parameters identified an 
excessive number of acellular capillaries in both control and experimental mice. 
Therefore, further criteria were included to capture and accurately represent the data.  
For the second round of development, it was judged to be essential to standardize the 
minimum length of an acellular capillary. Thus, a capillary is considered to be acellular if 
it lacks nuclei along a length greater than two standard deviations above the mean 
internuclei distance; with internuclei distance defined as the distance between nuclei 
along the same capillary. Hence, prior to determining if a capillary is acellular, it is 
necessary to measure the internuclei distance in the retinal microvasculature using the 
Euclidean distance formula among the controls and iDTR; M-Cre mice (10 images per 
animal, n=4 animals per group) to ascertain the mean. Once the mean internuclei distance 
	   102	  
in the retinal microvasculature from the controls and iDTR; M-Cre mice was established, 
the standard deviation was calculated and the length of two standard deviations above the 
mean internuclei distance was determined. The following equation was used to identify 
acellular capillaries (MinInternucliDist):  
MinInternucleiDist = meanInternucleiDistance + 2*stdInternucleiDistance 
Using these parameters, the algorithm determined which vessels contained no nuclei in a 
distance equal to MinInternucleiDist. However, a new challenge arose at this stage of 
development. Although some capillaries clearly appeared to be acellular by visual 
analysis, they were misclassified as cellular by the algorithm because of the proximity of 
nuclei from adjacent vessels. To address this issue, Wimasis Imaging Analysis iteratively 
fit my manual analysis into the algorithm (Figure 28) and produced the following final 
equation to identify acellular capillaries: 
MinInternucleiDist = 4*(meanInternucleiDistance + 2*stdInternucleiDistance) 
One caveat of using this algorithm for quantifying acellular capillaries is that the 
internuclei distance varies depending on the number of images and the 
genotype/phenotype of the animals used. Consequently, it was necessary to identify 
which animal genotype would be used for calculating the mean internuclei distance. To 
minimize any bias that might be introduced by using one control over the other, both of 
the controls and the experimental mice (iDTR; M-Cre, DT-treated M-Cre, and DT-treated 
iDTR; M-Cre) were used to calculate the mean internuclei distance. Using all three 
groups yielded the largest internuclei distance and therefore the most stringent conditions 
for defining acellular capillaries.  
	   103	  
The other criteria for identification of acellular capillaries is that they be a minimum of 
one-fourth the width of a normal capillary. For this measurement to be conducted it was 
necessary to establish the width of a normal capillary. To this end, the algorithm 
measured the width of all capillaries with normal internuclei distance. If a capillary with 
an internuclei distance outside the normal range was detected, but did not meet the 
criteria of being at least one-fourth the width of a normal capillary, the capillary was not 
categorized as an acellular capillary. Vessels larger than capillaries were not considered 
in this analysis. For both cellular and acellular capillary lengths, the results are expressed 
in mm. 
The final algorithm for automated image analysis of acellular capillary quantification in 
mouse elastase digests (discussed above) was developed in collaboration with Wimasis 
Imaging Analysis and can be identified as, “Wim_Acellular_Capillaries_Beta_1.03.” 
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Figure 28. Automated image analysis for acellular capillary quantification.  
Vessels digested from retinas using elastase and stained with periodic acid-Schiff (PAS) 
and hematoxylin. (A) Manual detection of acellular capillaries (black arrows). (B) For 
algorithm development, acellular capillaries (green, black arrows) were defined as a 
capillary length greater than or equal to 4(average internuclei distance + 2STD) lacking 
nuclei and a minimum width of one-fourth that of a regular capillary. Scale bar = 100 
µm. 
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Supplemental Figure 1. 4-OH tamoxifen toxicity in the retina of iDTR; M-Cre mice. 
Fundus photography of iDTR; M-Cre mice eight- to 10-weeks post-IP injection with A) 
the active drug, 4-OH tamoxifen (500 ng in 225 µl corn oil) daily for five days or B) the 
precursor drug, tamoxifen, (500 ng in 225 µl corn oil) daily for three days. 4-OH 
tamoxifen showed signs of tamoxifen toxicity, as seen by tamoxifen crystal deposits 
(bracket) and retinal damage (arrow).  
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Supplemental Figure 2. Mural cell loss is associated with tortuosity in iDTR; M-Cre 
mice.  
Retinal flat mounts were stained for alpha smooth muscle actin (α-actin, green) to detect 
mural vascular cells (pericytes and smooth muscle cells). Areas with mural cell loss 
(arrowheads) were associated with vessel tortuosity in systemically (IP) DT-treated 
iDTR; M-Cre mice. Scale bar = 100 µm. 
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Supplemental Figure 3. DT treatment in iDTR; M-Cre mice is associated with 
decreased glycogen in the liver.  
Liver sections from iDTR; M-Cre (top left panel), DT-treated M-Cre (top right panel), 
and DT-treated iDTR; M-Cre (bottom two panels) mice were stained with periodic acid-
Schiff (PAS, pink) to detect glycogen and hematoxylin (purple) to detect nuclei. 
Decreased glycogen, indicated by white areas lacking PAS staining, was observed in DT-
treated iDTR; M-Cre mouse livers (bottom two panels), but varied among individual DT-
treated iDTR; M-Cre mice (bottom left panel vs. bottom right panel). Scale bar = 100 
µm. 
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Supplemental Figure 4. Light microscopy image selection for EC, pericyte, and 
acellular capillary automated quantification.  
Images (approximately 175 µm x 125 µm) were taken contiguously in groups of six 
(black grid) to avoid bias. A minimum of 10 groups of six images was taken per retina. 
Fields were randomly selected from each group of six images for quantification of ECs, 
pericytes, and acellular capillaries. Grid is not to scale and is intended only to illustrate 
the method of image selection used for quantification. Scale bar = 250 µm. 
 
 
 
 
 
 
 
 
 
